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1. Foreword 
1.1 Antimicrobial use in veterinary medicine 
The introduction of antimicrobial agents in human and veterinary 
medicine has been one of the most significant medical achievements of the 20th 
century. The first antimicrobial agents were introduced in the 1930’s, and a large 
number of new compounds were discovered in the following decades. However, 
shortly after the introduction, resistance began to emerge. Formerly the same 
Alexander Fleming, discoverer of penicillin, had seen the future of antibiotic 
resistance risk. “The time may come when penicillin can be bought by anyone in 
the shops”, he said in his Nobel lecture; “then there is the danger that ignorant 
man may easily underdose himself and by exposing his microbes to non-lethal 
quantities of the drug make them resistant” (Fleming, 1945). In all known cases 
emergence of antimicrobial resistance has eventually followed the introduction 
of a new antimicrobial compound (EMA, 2006). 
In veterinary medicine antibiotics are used in animals for therapeutic and 
prophylactic purposes in order to cure and prevent bacterial diseases. In these 
cases, antimicrobial are administered under veterinary control. Another use of 
antimicrobial agents in animals, although banned since 2006 in the European 
Union but still allowed in other non-European countries(USA, Japan, Australia, 
among others), is as growth promoters. In this case, drugs are added in sub-
therapeutic doses and for long periods of time in the feed of healthy animals, 
conditions that could further contribute to the selection of resistant bacteria 
(McEwen and Fedorka-Cray, 2002). 
It is estimated that the volumes of antimicrobials used in animals exceeds the use 
in human medicine worldwide, and nearly all the classes of antimicrobials that 
are used for humans are also being used in food animals, including the newest 
classes of drugs such as third- and fourth-generation cephalosporins, 
fluoroquinolones, glycopeptides, and streptogramins (Aarestrup et al., 2008). 
In animal production systems with high density of animals or poor biosecurity, 
the spread of infectious diseases is favoured, which leads more frequently to 
antimicrobial treatment and increases the need for prevention of those diseases 
(EMA, 2006). 
Regarding the knowledge about veterinary antimicrobials use in Europe, huge 
improvement has been made through the activities of the European Surveillance 
of Veterinary Antimicrobial Consumption (ESVAC). The third ESVAC report 
presented the results on antimicrobial consumption in animals in 25 European 
Countries. In this report, the magnitude of the animal population is quantified by 
means of the population correction unit (PCU). This PCU is a technical unit of 
measurement based on the estimated weight at treatment of livestock and 
slaughtered animals; one PCU is the representation of 1 kg of different 
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categories of livestock and slaughtered animals. As reported by the ESVAC 
report in 2011, a total of 8,481 tonnes of active ingredient of antimicrobials have 
been sold for veterinary use in the 25 EU countries. The sales of tetracyclines, 
penicillins and sulfonamides, in mg/PCU, accounted for more than 71% of the 
total sales (range 53%–88%). Among the so-called CIA (Critically Important 
Antibiotics), designated by the WHO as the molecules critical to human health, 
the sales percentages of 3rd and 4th generation cephalosporins, fluoroquinolones 
and macrolides were, respectively, 0.2%, to 1.6% and 8% of total sales in the 25 
countries in 2011. Another important finding was that the total sales, both in 
tonnes and in mg/PCU, of veterinary antimicrobial agents in the 25 EU/EEA 
countries were mainly accounted for pharmaceutical forms applicable for mass 
treatment (premixes, oral powder and oral solution) and this type of treatment is 
considered even more risky for the development of antimicrobial resistance.  In 
Italy, a decline in antimicrobials sales (in mg/PCU) of 13% from 2010 to 2011 
has been observed and the decline has been reported for almost all antibiotic 
classes (ESVAC, 2013). 
1.2 Overview of poultry production 
During the last 50 years, avian production increased enormously; the 
industry developed to be highly integrated, with fewer companies controlling 
most sources of birds, feed mills, farms, slaughter and processing facilities. 
Integration led to standardized management practices, including drug treatment 
policies and procedures and to many successes in the prevention and control of 
infectious diseases (McEwen and Fedorka-Cray, 2002). 
The European Union (EU) is one of the world's top producers in poultry meat 
and a net exporter of poultry products. Over the years the market organisation 
for poultry sector was improved to ensure the development of the sector, the 
quality of the products and consumers protection while harmonizing the entire 
market. In 2012, the total poultry meat production in the EU was 12.9 million 
tonnes, with an increase of 14% compared to 2007. Broilers meat is the main 
poultry meat with a total production of 9.9 million tonnes in 2012. In Europe, 
the leading producers of broilers meat, with a production above 0.7 million 
tonnes each, are the UK, Poland, Germany, France, Spain, Italy and the 
Netherlands. All these countries together are responsible for 76% of the EU's 
poultry meat production. Besides broilers, turkeys are also an important 
subsector. In 2012, total turkey meat production in the EU was 1.9 million 
tonnes. The main producing countries of turkey meat are France, Germany, 
Poland, Italy and the UK, with a common share of 81% of the EU total (AVEC 
annual report, 2014). 
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1.3 Antimicrobial drug use in poultry industries 
In highly organized and intensive avian production, every disease outbreak 
has a major effect on health and welfare, leading to a decreased technical 
performance and profitability. Shorter production cycles, through improved 
genetics and diet, have led to the fact that there is little recovery time for animals 
after a disease outbreak. In case of endemic diseases, their outbreaks will 
predominantly result in economic losses for individual farmers, whereas in case 
of epidemic diseases, the entire poultry production sector may be involved 
through mandatory preventive measures such as quarantine or destruction of 
poultry (Gelaude et al., 2014). 
Since commercial poultry are food animals the choice of antimicrobials is 
affected by the issue of drugs residues in edible tissues. In Europe, only those 
antimicrobials for which a maximum residue level (MRL value) is set can be used 
in poultry flocks. The withdrawal period indicates the time which pass between 
the last dose given to the animals and the time when animals can enter in the 
food chain. The relatively short lifetime of the meat producing poultry species 
and the importance to guarantee the withdrawal time can significantly limit the 
availability of therapeutic options (Lohren et al., 2008). 
Another important aspect in determining the drug to use is the economical 
factor: in avian species the low economic value of individual birds makes single 
therapy cost-prohibitive. Therefore, due to the enormous number of animals 
bred, the oral mass therapy becomes a forced choice (Hofacre et al., 2013). 
The most important antimicrobial classes used in avian medicine are listed in the 
table below (Lohren et al., 2008): 
Antimicrobial class Drug name Type of activity 
Aminoglycosides 
apramycin 
gentamicin 
neomycin 
spectinomycin 
streptomycin 
 
Bactericidal 
Sulfonamides 
sulfadiazine 
sulfadimethoxine 
Bacteriostatic 
Potentiated sulfonamides trimethoprim and sulfonamides Bactericidal 
β-Lactames 
benzylpenicillin 
potassium penicillin G 
ampicillin 
amoxicillin 
ceftiofur 
Bactericidal 
Fluoroquinolones 
enrofloxacin 
difloxacin 
flumequine 
Bactericidal 
Lincosamides lincomycin Bacteriostatic 
Macrolides erythromycin Bacteriostatic 
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spiramycin 
tylosin 
tilmicosin 
Pleuromutilines tiamulin Bacteriostatic 
Polypeptides colistin sulfate Bactericidal 
Tetracyclines 
tetracycline 
chlortetracycline 
oxytetracycline 
doxycycline 
 
Bacteriostatic 
For poultry, the preferred method of treatment is oral medication, via drinking 
water or feed medication. This is because large numbers of birds can be 
medicated at the same time. However, in the case of acute disease with serious 
losses of animals, parenteral therapy offers a valuable alternative; the method of 
medication is often complicated by other factors such as animal welfare, 
avoidance of tissue damage and stress (Vermeulen et al., 2002). The major 
consideration in determining the method of administration to birds is ease of 
management. The formulation of a drug intended for use in avian species is 
frequently dictated by the need for a practical and economical method of 
administration. When a feed-based antimicrobial is prescribed, the time required 
for the manufacturing, transporting and delivering through the feeding system at 
the farm must be taken into account; whereas the administration of the antibiotic 
in drinking water allows faster treatment (Hofacre et al., 2013). Drinking water 
therapy offers several advantages and few disadvantages. Important advantages 
are the low cost of management, the low work load, the ease of administration 
and a quick change of drug and/or dose is possible. Besides, diseased birds 
usually tend to stop eating, but they will continue to drink. The main 
disadvantages are: drug uptake can vary dramatically as a function of the animal, 
unprofessional use and a wrong preparation of the medical solution by the 
farmer and possible solubility and stability problems (Vermeulen et al., 2002). At 
first sight, this technique seems simple but many more variables have to be taken 
into account, these include: the water quality, the individual water uptake, the 
influence of drinking water system and the lighting periods. Basically, the water 
should be clean, cool and neutral in taste. The water should be replaced daily and 
soiling of the drinking water should be avoided because of possible drug 
inactivation. Several water quality parameters which may influence the use of an 
oral medication are hardness, the pH values, dissolved solids and a high mineral 
content (Esmail, 1996). 
Medication use is mainly indicated as mg per kg body weight and this means that 
information on daily water intake as function of poultry species, flock size, 
weight and age on the moment of treatment must be available. The drinking 
water intake varies greatly depending upon different factors such as 
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environmental temperature, density and composition of the diet (Vermeulen et 
al., 2002). 
Finally, the treatments via drinking water can be conducted following two types 
of schemes: continuous administration during the entire light period or pulsed 
administration for a limited period between 4 and 10–12 h(Charleston et al., 
1998). 
1.4 Antimicrobial resistance 
Overuse and misuse of antimicrobial drugs have favoured the growth of 
resistant organisms and resistance can spread to other microbial populations, 
jeopardizing human and animal health (Toutain et al., 2002).  
Antimicrobial resistance, defined as the ability of a microorganism to withstand 
the effect of a normally active concentration of an antimicrobial agent, is a global 
phenomenon and a well-recognised threat to public as well as animal health. The 
causal factors in the development of resistance are many and complex, but 
originate generally from exposure of microorganisms to antibiotics (Marshall and 
Levy, 2011). 
The development of resistance is a natural process which increases every time an 
antibiotic is used. The initial emergence of resistance is thought to be a random 
occurrence that arose during replication of bacteria. However, once resistance 
has occurred, the use of an antibiotic kills or inhibits competing bacteria present 
in the animal or human, thereby favouring the spread of those bacteria that have 
become resistant. This defensive mechanism whereby resistance genes are 
selected in the face of exposure to a particular antibiotic is known as selection 
pressure. The more often exposure occurs, the greater the risk that resistance 
will develop. As bacteria reproduce very rapidly, organisms with the resistant 
gene can rapidly become dominant in a bacterial population with an individual 
animal or human (Coates, 2012). 
In human medicine it is generally agreed that the improper use of antimicrobial 
agents is the most important factor in the selection of resistance in bacteria and 
that, in general, a close association exists between the rate of resistance 
development and the quantities of antimicrobial agents used (Aarestrup, 1999). 
Human infections caused by resistant bacteria are more frequently associated 
with higher morbidity and mortality than those caused by susceptible pathogens. 
In areas of concentrated use, such as hospitals, this has led to lengthened 
hospital stays, increased health care costs and, in extreme cases, to untreatable 
infections (Boerlin and White2006). 
Antimicrobial resistance mechanisms have been reported for all known 
antibiotics currently available for clinical use in human and veterinary medicine. 
Therefore, successful sustainable management of current antimicrobials and the 
continued development of new ones and of alternatives to antimicrobial drugs 
16 
 
are vital to protecting animal and human health against infectious microbial 
pathogens (Martinez and Silley, 2010). 
1.4.1 Resistance mechanism 
Antimicrobial resistance mechanisms can be classified into four major categories: 
1) the antimicrobial agent can be prevented from reaching its target by reducing 
its penetration into the bacterial cell; 2) the antimicrobial agent can be expelled 
out of the cell by general or specific efflux pumps; 3) the antimicrobial agent can 
be inactivated by modification or degradation, either before or after penetrating 
the cell; and 4) the antimicrobial target can be modified or protected by another 
molecule preventing access of the antibiotic to its target, so that the 
antimicrobial cannot act on it anymore. Alternatively, the antimicrobial agent 
target can be rendered dispensable by the acquisition or activation of an alternate 
pathway by the microorganism (Boerlin and White, 2013). 
1.4.2 Types of antimicrobial resistance 
In the context of antimicrobial resistance, bacteria display three fundamental 
phenotypes (Boerlin and White2006): 
 susceptibility that implies that isolates are inhibited by the usually 
achievable concentrations of antimicrobial agent when the recommended 
dosage (dosage regimen) is used for that site of infection (CLSI, 2007) 
 intrinsic resistance, that is the innate ability of a bacterial species to 
resist the activity of a particular antimicrobial agent through its inherent 
structural or functional characteristics, which allow tolerance of a 
particular drug or antimicrobial class (Boerlin and White2006). 
 acquired resistance, it occurs when a particular microorganism obtains 
the ability to resist the activity of a particular antimicrobial agent to which 
it was previously susceptible. This can result from the mutation of genes 
involved in normal physiological processes and cellular structures, from 
the acquisition of foreign resistance genes or from a combination of these 
two mechanisms. Acquired resistance can be manifested as resistance to a 
single agent, to some but not all agents within a class of antimicrobial 
agents, to an entire class of antimicrobial agents, or even to agents of 
several different classes. (Boerlin and White2006). 
In the great majority of cases, a single resistance determinant encodes resistance 
to one or several antimicrobial agents of a single class of antimicrobials or of a 
group of related classes of antimicrobials (Mayer, 2009). 
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1.4.3 Transfer of antimicrobial resistance from animals to human 
The use of antibiotics in food producing animals contributes to the selection of 
resistant bacteria that can be transferred from animals to humans. The food 
chain is considered as a transmission vehicle of resistant bacteria to humans. The 
risk to transfer antimicrobial resistance arises via the consumption of product 
(milk, eggs, honey, meat) from treated animals, but also by the contact with 
treated animals, being they pets or food-producing animals, or their environment 
(Aarestrup, 1999). 
Nowadays, there is considerable evidence that antimicrobial use in animals 
selects for resistance in zoonotic enteropathogens and in commensals bacteria 
(Garcia-Migura et al., 2014).Antimicrobial resistance in zoonotic 
enteropathogens (e.g., Salmonella, Campylobacter, Yersinia, and some strains of 
pathogenic E. coli) and commensals (e.g., enterococci, mostly E. coli) is of special 
concern to human health and various European countries have implemented 
national monitoring programs [e.g. Denmark (DANMAP), France (FARM), 
Netherlands (MARAN), Norway (NORM-VET), Sweden (SVARM) and Spain 
(VAV)]to assess susceptibility to antibiotics among these bacteria isolated from 
healthy food animals (DANMAP report, 2013, FARM report, 2013, MARAN 
report, 2013, NORM-VET report, 2013, SVARM report, 2013, VAV report, 
2005). 
If commensal bacteria, which are naturally occurring in the host, are exposed to 
antimicrobial agents, they may become resistant and be able to transfer 
resistance genes to pathogenic bacteria. Antimicrobial resistance in the 
commensal bacteria of humans and animals results largely from the selective 
pressure of antimicrobial agents use and reflects the genetic elements that may 
transfer to pathogens. The above cited zoonotic bacteria are considered 
responsible of important infections in food animal species; fluoroquinolones and 
cephalosporines are antimicrobials frequently used against these pathogens. An 
increase in resistant strains of E. Coli, Campylobacter and Salmonella has been 
reported in recent years. In particular high level of resistance was reported in 
bacteria strains isolated from poultry and turkeys (EFSA, 2010). 
In the United States in 2005, two fluoroquinolones that were approved for the 
control of colibacillosis in poultry were banned. The primary reason for this ban 
was exactly to allay concerns regarding rising fluoroquinolones resistance rates in 
human cases of camplylobacteriosis. (FDA, 2005). 
In Countries were fluoroquinolones are not use in poultry, such as Australia, the 
resistance phenomenon in Campylobacter, Salmonella and E. coli are rare and 
consequently resistance in human is also much lower than in most countries 
(Cheng et al., 2012). 
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1.5 Judicious use of antimicrobial drugs 
In order to minimize the possible impact of animal antimicrobial usage on 
public and animal health, various international organizations such as WHO, 
OIE, FAO and EU Commission have, in recent years, emphasized the 
importance of prudent and rational use in veterinary medicine . This has been 
recognized by professional associations as well as by national and international 
authorities. All these institutions have underlined to a lesser or greater degree 
that prudent antimicrobial use is important, not only to safeguard the efficacy of 
antimicrobial drugs in veterinary medicine but, even more so, to prevent the 
emergence and spread of undesirable resistance phenotypes in zoonotic 
pathogens as well as in commensal bacteria that can be transmitted between 
animals and humans (Teale and Moulin, 2012).  
There are no finite definitions of “prudent” and “rational” in relation to 
antimicrobial use. Both terms are frequently used to suggest a responsible 
attitude to antimicrobial use, aimed at minimizing the development and spread 
of antimicrobial resistance while maximizing therapeutic efficacy. This attitude, 
and its objectives, apply both to human and veterinary medicine. Sometimes the 
terms prudent and rational are used more or less synonymously. However, they 
refer to slightly different aspects. prudent use has the overall goal of reducing 
antibiotic usage, with particular emphasis on the relative use of broad spectrum 
and critically important drugs. Rational use refers to rational administration of 
antimicrobials to the individual with the purpose of optimizing clinical efficacy 
while minimizing development of resistance. Judicious use of antibiotics, both in 
humans and in animals, is a key factor to minimize the risk of selecting resistant 
bacteria and help keep antibiotics effective for future generations (Guardabassi 
and Kruse, 2008). 
The best way to reduce the need for and use of antimicrobials and thereby aiding 
the containment of resistance phenomenon, is by preventing disease. Prevention 
is better than cure, not only in relation to antimicrobial resistance, but also from 
an animal welfare prospective and from economic viewpoint. In this regard 
several management techniques including good biosecurity rules and specific 
vaccination programs are routinely used in intensive farming in order to limit as 
much as possible the need for antibiotics (Laanen et al., 2014). 
In veterinary medicine, prudent use of antibiotics is an integral part of good 
veterinary practices. Prudent use principles should not be interpreted so 
restrictively as to replace professional judgment of practitioners or to 
compromise animal health or welfare. In all cases, animals should receive 
prompt and effective treatment as deemed necessary by the prescribing or 
supervising veterinarian (FVE, 1999). 
General prudent use guidelines have been developed in recent years by most 
national and international veterinary organizations, mostly providing statements 
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of principles of judicious antimicrobial use. For example the Food and Drug 
Administration, Center for Veterinary Medicine, in cooperation with the 
American Veterinary Medical Association has drafted a list of points to consider 
in order to optimize the use of antibiotics in poultry farms (FDA, CVM): 
 Preventive strategies, such as appropriate husbandry and hygiene, 
routine health monitoring, and immunization, should be 
emphasized. 
The foundation of the success in the poultry industry is through disease 
prevention management. Farms utilizing all-in-all-out production 
minimize the presence of multiple ages of flocks on farms to help in 
disease prevention. Biosecurity programs in place on poultry farms 
prevent the introduction of diseases. 
 Other therapeutic options should be considered prior to 
antimicrobial therapy. 
The poultry industry approaches the treatment of diseases with 
antimicrobial agents very seriously. Because of the cost of disease 
treatment with antimicrobials, therapeutic antimicrobial intervention is 
used only as a tool to treat active disease. 
 Judicious use of antimicrobials, when under the direction of a 
veterinarian, should meet all requirements of a valid veterinarian-
client-patient relationship. 
Poultry veterinarians, in integrated companies, closely monitor 
antimicrobial use in their poultry flocks. They maintain close contact with 
service technicians and managers related to the use of antimicrobials. 
Veterinarians should be involved in the training of all individuals that will 
ultimately be following veterinary directions for antimicrobial use. 
Antimicrobials should be used always under the direction and knowledge 
of the company veterinarian or veterinary consultant. 
 Regimens for therapeutic antimicrobial use should be optimized 
using current pharmacological information and principles. 
For the purpose of correct use a precise diagnosis and antimicrobial 
susceptibility testing are essential. The choice of an appropriate drug 
product and the administration route should also be considered when you 
have to treat diseased animals. Likewise an appropriate dosage regimen 
(dose level, dose interval and treatment duration) is of fundamental 
importance to minimize therapy failures, exploit the efficacy potential of 
the drug and comply with the regulated withdrawal times. Low doses, 
increased intervals and reduced treatment periods can lead to 
redevelopment of the infection and may increase the risk of selecting 
resistant organisms.  
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 Therapeutic exposure to antimicrobials should be minimized by 
treating only for as long as needed for the desired clinical response 
and therapy should be limited to ill or at risk animals. In population 
medicine involving flocks, it is recognized that in a disease outbreak, all 
birds are not infected at the same time with the disease to which 
antimicrobial therapy is warranted. However, birds in the same house are 
“at risk” to the same primary disease that often results in secondary 
bacterial infections. Only birds within the same house ill or at risk are 
treated. 
 Minimize environmental contamination with antimicrobials 
whenever possible. 
Even more importance and attention is now given to the prudent use of 
medically important antimicrobial drugs, a term that refers to those drugs for 
human therapeutic use. In recent years the European Medicines Agency (EMA), 
acting at the request of the European Commission, has reviewed the indications 
and conditions under which a number of the more modern antibiotic classes 
(fluoroquinolones, macrolides and cephalosporins) are used in veterinary 
medicine. These reviews have resulted in the elaboration of more precise 
recommendations for use and new warnings which must be taken into account 
by vets when prescribing these antibiotics (EMA, 2011). 
In some marketing authorizations in the EU, special precautions for use have 
been added to the Summary of Product Characteristic (SPCs) of fluoroquinolone 
products. For the fluoroquinolones, at EU level, the risk evaluation is still 
ongoing and it has been decided that risk management measures has to be 
implemented to maintain their efficacy for veterinary use. These include the 
following: fluoroquinolones should be reserved for the treatment of clinical 
conditions which have responded poorly, or are expected to respond poorly, to 
other classes of antimicrobials; their dosage regimens should be carefully 
determined on the basis of and pharmacodynamic properties to ensure optimal 
efficacy and reduce selection of resistance (EMA, 2006). 
1.6 Pharmacokinetic/pharmacodynamics approach to a rational 
dosage regimens 
There are several possibilities to limit the development of antimicrobial 
resistance phenomenon. They include research into the mechanisms and 
diffusion of resistance; the search of new drugs and alternative to antibiotic use; 
proper attention to preventive measures and commitment to prudent use (Wise, 
2003). 
For a rational and judicious antibiotic therapy, dosage regimens have to be 
optimized, both to guarantee clinical efficacy and to minimize the selection of 
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resistant pathogens. In veterinary practice, one of the most important risk factor 
for emergence of resistance is repeated exposure of bacteria to sub optimal 
concentrations of antibiotics (Toutain and Lees, 2006). This event is even more 
frequently when considering the mass treatment with feed or water medication 
often adopted in animal husbandry (Wise, 2003). 
In humans many studies have been carried out to define precise dosages, to 
improve drug activity and reduce selection of resistance in antimicrobial therapy 
(Rybak, 2006). Many of these studies use “so called” models (PK/PD) that 
correlate the antimicrobial pharmacokinetics (PK) with the action on pathogens 
by pharmacodynamics (PD). PK, is the study of time course of absorption, 
distribution, metabolism and elimination of drugs, while PD is the study of the 
efficacy of the drug on causative bacteria determining the minimum inhibitory 
concentration (MIC) (Toutain et al., 2002). 
PK/PD modelling provides surrogate markers for clinical and bacteriological 
efficacy based on the relationship between serum/tissue concentrations of 
antimicrobial agents and MIC and has great potential for optimal dosage regimen 
determination (Toutain and Lees, 2006). 
The use of PK/PD principles for evaluation of antimicrobial compounds has 
become common also in the veterinary literature. Most papers published in the 
last few years in veterinary journals discuss the features of PK in light of the PD 
of the drug and how this relates to rational dosage regimens; the results confirm 
the high potential of PK/PD modeling to define more rational dosages and the 
significant variable to consider is the plasma concentration time profile (Papich, 
2014). 
The differences in pharmacokinetics between different species exist and are well 
documented. Studies to define the dosage are often made in the species 
considered major, but to optimize the effectiveness and avoid underdosing 
precise studies should be carried out in the target species of the drug (Toutain et 
al., 2010). 
One mechanism to reduce the risk of emergence of resistant bacteria is to use 
the agents currently available to veterinarians more effectively. This means 
administration of sufficient dosages and appropriate regiments that meet the 
PK/PD targets for each antimicrobial drug class. In veterinary therapy the 
efficacy confirmation of dosage schemes is necessary, correlating the kinetic 
profile of both authorized doses and higher doses, often used in practice, with 
the in vitro efficacy evaluation of field isolated strains, known as more resistant 
(Mc Kellar et al., 2004). 
To determine bacteriostatic or bactericidal effects, main PK/PD indices result 
from combination of blood concentration parameters, as maximum or minimum 
concentrations, (Cmax and Cmin, respectively), half-life, area under the curve 
(AUC) with PD characteristics, as sensitivity, MIC, minimum bactericidal 
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concentration (MBC). The indices that best correlate kinetics and efficacy are the 
ratio between AUC calculated from 0 to 24 h (AUC0-24) and MIC (AUC0-
24/MIC), between Cmax and MIC (Cmax/MIC) and the time during which blood 
concentrations exceed the MIC (T>MIC). All these indices (breakpoints) are 
particularly useful to optimize efficacy and minimize resistance of antimicrobials 
used in therapy (Toutain and Lees, 2006). 
The PK/PD indices are also now used to derive breakpoints by the Clinical and 
Laboratory Standards Institute (CLSI; formerly NCCLS) subcommittee on 
Veterinary Antimicrobial Susceptibility Testing (VAST) (Papich, 2014). 
1.7 Fluoroquinolones 
1.7.1 History of fluoroquinolones 
The fluoroquinolones, also known as quinolones, 4- quinolones and quinolone 
carboxylic acids, are a large and expanding group of synthetic antimicrobial 
agents. The history of quinolone agents began with the discovery of nalidixic 
acid in 1962 as an accidental byproduct during the synthesis of antimalarial 
compound, chloroquine (Lesher and Froelich, 1962). The nalidixic acid was the 
first 4-quinolone marketed for clinical use. However, the effectiveness of 
nalidixic acid was limited due to poor absorption and distribution, narrow 
spectrum of activity including the tendency to select for resistant organisms 
during the course of therapy, and its toxic effect on the host. Over the next two 
decades hundreds of analogues of nalidixic acid were synthesized but only a few 
(such as pipemidic acid, oxolinic acid and flumequine) were used clinically. 
Despite chemical modifications to the basic 4-quinolone molecule, these 
products had many of the same limitations that affected the clinical use of 
nalidixic acid, restricting their use principally to the treatment of urinary 
infections. The success for this class of antibacterial agents came when a fluorine 
atom and a piperazine ring were attached to the 6- and 7- positions, respectively, 
of the basic quinolone nucleus. These substitutions increased absorption, 
increased antibacterial activity and reduced toxicities (Ball, 2000). The first of 
these newer agents used clinically was norfloxacin that exhibited activity against 
many common bacterial pathogens but was less active against more troublesome 
organisms such as Pseudomonas aeruginosa (Koga et al., 1980). Structurally, 
norfloxacin differed from nalidixic acid and the substitutions performed 
increased the activity against Gram-positive and Gram-negative bacteria 
(Schentag and Scully, 1999). Compared to original quinolones, these compounds 
possess superior pharmacokinetic characteristics, such as good bioavailability 
when given orally, greater tissue penetration, and a longer half-life. Since then, a 
large number of new molecules, many of them polifluorate derivatives, have 
been synthesized (Escribano et al., 1997). 
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The fluoroquinolones are classified into different groups or generations based on 
their chemical structure or their biological activities. The biological classification 
places fluoroquinolones in three groups of generations; the first-generation 
molecules are those with antibacterial activity restricted to the Enterobacteriaceae. 
Second-generation quinolones have an extended spectrum of activity whereas 
the third-generation exhibited considerable improving of activity also against 
streptococci and obligate anaerobes(Martinez et al., 2006). 
Just at the beginning of the 1980’s,the first older generation quinolones (e.g. 
oxolinic acid and flumequine) were licensed for use in food animals and during 
the late1980’s and early 1990’s, also the first fluoroquinolones. To date there 
have been eight fluoroquinolones approved for use in veterinary medicine: 
danofloxacin, difloxacin, enrofloxacin, ibafloxacin (Europe only at this time), 
marbofloxacin, orbifloxacin, pradofloxacin and sarafloxacin (Giguère and 
Dowling, 2013). 
1.7.2 Mechanism of action  
Fluoroquinolones act by inhibiting two enzymes involved in bacterial DNA 
synthesis, both of which are DNA topoisomerases that human cells lack and that 
are essential for bacterial DNA replication, thereby enabling these agents to be 
both specific and bactericidal. DNA topoisomerases are responsible for 
separating the strands of duplex bacterial DNA, inserting another strand of 
DNA through the break, and then resealing the originally separated strands. 
Specifically, fluoroquinolones inhibit DNA gyrase (topoisomerase II) and 
topoisomerase IV. DNA gyrase introduces negative superhelical twists in the 
bacterial DNA doublehelix ahead of the replication fork, thereby catalyzing the 
separation of daughter chromosomes (Blondeau, 2004). This activity is essential 
for initiation of DNA replication and allows for binding of initiation proteins. 
The topoisomerase IV enzyme is a secondary fluoroquinolone target and it is 
responsible for decatenation that is, removing the interlinking of daughter 
chromosomes thereby allowing segregation into two daughter cells at the end of 
a round of replication. Fluoroquinolones interact with the enzyme-bound DNA 
complex (i.e., DNA gyrase with bacterial DNA or topoisomerase IV with 
bacterial DNA) to create conformational changes that result in the inhibition of 
normal enzyme activity (Martinez et al., 2006). As a result, the new drug– 
enzyme–DNA complex blocks progression of the replication fork, thereby 
inhibiting normal bacterial DNA synthesis and ultimately resulting in rapid 
bacterial cell death (Blondeau, 2004).  
A peculiarity of these antimicrobials is their biphasic concentration-response 
curve (paradoxical effect). Survival curves show that when the fluoroquinolone 
concentration is near the minimal inhibitory concentration (MIC) of bacterium, 
the drug has a static effect on bacterial growth (bacteriostatic). As the 
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concentration increases relative to the MIC, bacterial killing increases up to a 
certain drug concentration termed the optimum bactericidal concentration. As 
concentration exceed the optimum bactericidal concentration, further increases 
in drug concentration can lead to a decrease in bacterial killing. Initially these 
concentration-related differences in drug effect may be associated with the 
difference between concentrations needed to inhibit DNA supercoiling versus 
those needed to inhibit bacterial growth. In general, it appears that the 
supercoiling reaction of gyrase is less sensitive to the drugs than is bacterial 
growth by one or two orders of magnitude (Martinez et al., 2006). 
1.7.3 Spectrum of activity 
The fluoroquinolones have excellent activity in vitro against a wide range of 
aerobic Gram-negative bacteria, including the Enterobacteriaceae, 
Actinobacilluspleuropneumoniae, Histophilussomni, Mannheimiahaemolytica, and Pasteurella 
spp. including P. multocida. They are also active against Bordetellabronchiseptica, 
Brucella spp., and Chlamydia/Chlamydophila spp. (Giguère and Dowling, 
2013).Fluoroquinolones also have significant activity against veterinary 
mycoplasmas (Govendir et al., 2011). Activity against Pseudomonasaeruginosa is 
dependent on the compound, with ciprofloxacin being the most potent agent 
against this bacterium (Van Bambeke et al., 2005). Generally, the first- and 
second-generation fluoroquinolones are less active against Gram-positive 
bacteria, especially enterococci, and have poor activity against anaerobic bacteria. 
The third-generation of fluoroquinolones target this deficiency. For example, 
trovafloxacin, moxifloxacin, and gatifloxacin are newer fluoroquinolones with 
good in vitro activity against obligate anaerobes (Stein and Goldstein, 2006). 
Most fluoroquinolones approved for use in veterinary medicine should be 
considered to be ineffective against obligate anaerobes. The only exception is 
pradofloxacin, which is active against anaerobic bacteria from dogs and  cats 
including Clostridium spp., Bacteroides spp., Fusobacterium spp., and Prevotella spp. 
(Silley et al., 2007). 
1.7.4 Resistance mechanisms 
Resistance to the fluoroquinolones occurs by target modification, decreased 
permeability, efflux and/or target protection. Each of these fluoroquinolones 
resistance mechanisms can occur simultaneously within the same cell, thereby 
leading to very high resistance levels (Giguère and Dowling, 2013). 
The major mechanism of quinolone resistance is alteration of the target enzymes 
of fluoroquinolones, DNA gyrase and topoisomerase IV.Both enzymes are 
composed of 2 pairs of subunits: GyrA and GyrB in DNA gyrase, ParC and ParE 
in DNA topoisomerase IV. Resistance to fluoroquinolones occurs as a result of 
changes in amino acid composition, particularly in the Quinolone-Resistance-
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Determining Regions (QRDRs) within GyrA and ParC, making the target 
enzymes less susceptible to fluoroquinolones (Fàbrega et al., 2008). Among 
Gram-negative organisms, quinolone resistance typically develops in a stepwise 
manner. A single QRDR mutation, usually at serine 83 (Ser83), confers 
resistance to nalidixic acid and decreases susceptibility to fluoroquinolones; 
secondary mutations in the GyrA QRDR lead to overt fluoroquinolone 
resistance. However, this does not apply to all Gram-negative bacteria. In 
Campylobacter, which lacks topoisomerase IV, a single mutation in GyrA is 
sufficient to impart high-level of MICs (Wang et al., 1993). This feature helps 
explain the higher prevalence of resistance in Campylobacter, compared with E. 
coli, from food animals exposed to fluoroquinolones (Van Boven et al., 2003). 
While mutations in the quinolone target genes are required to achieve a clinical 
level of resistance, several other mechanisms may also contribute to resistance, 
including decreased intake of the drug due to the loss of a membrane-bound 
porin; drug extrusion via efflux pumps, some of which may have a broad 
substrate specificity; or one of the more recently described plasmid-mediated 
quinolone resistance (PMQR) mechanisms (Karczmarczyk et al., 2011). 
1.7.5 Pharmacokinetic properties 
Generally these compounds are characterized by a high volume of distribution, 
long biological half-life, low serum protein binding, elimination by renal and 
extrarenal mechanisms with high total and renal clearances, limited 
biotransformation and moderate to excellent bioavailability after oral 
administration (Giguère and Dowling, 2013). 
The fluoroquinolones used in veterinary medicine are primarily administered 
orally although parental formulations are available for administration to dogs, 
cats, horses and food animals. Although there is considerable individual variation 
among the different compounds and in the different animal species, the 
fluoroquinolones are rapidly absorbed following oral administration in 
monogastric species; bioavailability is rather low in ruminants although the 
reason for has not been determined (Brown, 1996). 
When fluoroquinolones are co-ingested with food the time to reach peak 
concentration (Tmax) may be delayed but the maximum concentration (Cmax) is 
unaffected. However, concomitant administration with products that contain 
metal cations (such as Fe, Ca, Mg), will adversely affect the Cmax. Parenteral 
bioavailability of most quinolones is approximately complete in pre-ruminants 
and ruminants cattle (Thomas et al., 1994a). 
Following absorption, fluoroquinolones exhibit rapid and extensive tissue 
distribution because of their physicochemical properties; moreover they have the 
capacity to penetrate nearly all organs and cells. Their apparent volumes of 
distribution exceed total body water (> 1 L/kg).As with other antibiotics which 
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exhibit intracellular accumulation (e.g. tetracyclines, macrolides), the 
concentrations of fluoroquinolones in different tissues are often higher than the 
concurrent serum levels. Fluoroquinolones are able to concentrate within 
phagocytic and non-phagocytic cells and remain active against different 
facultative, obligate, intracellular pathogens (Brown, 1996). In most species, this 
distribution volume over 3 times greater than that of most ß-lactam antibiotics 
and aminoglycoside, and probably represents intracellular sequestration of the 
drug in various tissues. The very good distribution of these drugs is also due to 
their low plasma protein binding (<50%) (Giguère and Dowling, 2013). 
Fluoroquinolones undergo a partial hepatic metabolism and give rise to active 
metabolites that are excreted in bile and urine. Fluoroquinolone metabolic 
pathways include glucuronidation, N-oxidation and desmethylation. Generally, 
metabolism involves the CYP 450 system (Martinez et al., 2006). 
For example, the major metabolite of enrofloxacin is ciprofloxacin; the amount 
of ciprofloxacin produced varies with different species, with some producing 
ciprofloxacin concentrations that exceed the MIC of some pathogens (Kung et 
al., 1993). 
Elimination may be via liver or kidneys or both depending on the compound. 
The fluoroquinolones are predominantly excreted as unchanged drug in the 
urine by glomerular filtration and active tubular secretion. The exception is 
difloxacin, where 80% is excreted in the feces. The elimination half-life of the 
fluoroquinolones is dependent on the drug and the animal species, and may also 
be dose dependent. The long elimination half-lives make these compounds ideal 
for every 24 or 48 hour dosing regimens (Giguère and Dowling, 2013). 
1.7.6 Pharmacodynamic properties and PK/PD correlation  
With ideal pharmacokinetic characteristics but a potential to select for resistant 
bacteria, optimal therapeutic dosage regimens for fluoroquinolones requires, as 
previously described, the PK/PD integration (Giguère and Dowling, 2013). 
The universally recognized variable, which provides a quantitative index of drug 
efficacy and potency, is MIC and it is defined as the lowest concentration which 
completely inhibits bacterial growth. MBC is an alternative, but less frequently 
used, measure of potency. It is the drug concentration that produces a 99.9% 
reduction in bacterial count. Another PD variable, used specifically in relation to 
antimicrobial resistance acquired by mutation (e.g. quinolone resistance), is 
mutant prevention concentration(MPC), which is defined as the concentration 
that does not allow any mutant to be recovered from a population of more than 
1010 microorganisms (Lees et al., 2008). 
The best parameters associated with fluoroquinolones efficacy are AUC0-24/MIC 
or Cmax/MIC ratios (Toutain and Lees, 2006). For fluoroquinolones, several 
authors reported that resistance selection may be reduced by achieving an   
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AUC0-24/MIC ratio > 100 h or a Cmax/MIC ratio > 8 for concentration-
dependent antimicrobial drugs. Other authors recommended,  ratios > 125 h for 
AUC0-24/MIC or a Cmax/MIC > 10 to achieve high efficacy (McKellar et al., 
2004).Furthermore, differences result if efficacy is determined against Gram-
negative or Gram-positive strains. For the former microorganisms the ratio to 
ensure bacterial cure and prevent the selection of resistant bacteria should be 
approximately 125, while with the latter the ratio can be as low as 30-50 
(Martinez et al., 2006). The exact AUC/MIC ratio that would predict outcome of 
infection in domestic animals would likely vary according to animal species, 
infectious agent, site of infection, immune status of the host, and specific 
fluoroquinolones selected (Giguère and Dowling, 2013). 
1.7.7 Adverse effects 
Fluoroquinolones are relatively safe antimicrobial drugs. When administered at 
therapeutic doses, toxic effects are mild and generally limited to gastrointestinal 
disturbances such as nausea, vomiting, and diarrhea. Chronic, high-dose 
fluoroquinolone therapy causes articular cartilage lesions in juvenile dogs, 
particularly in weight bearing joints (Burkhardt et al., 1992). 
Retinal degeneration has been reported in cats treated with high doses              
(20 mg/kg every 24 hours) of enrofloxacin (Wiebe and Hamilton, 2002). 
Neurotoxic effects causing central nervous system disturbances (seizures, 
dizziness, ataxia, insomnia, restlessness, somnolence, tremors) are common 
adverse effects of fluoroquinolones in humans and have been reported in horses, 
dogs and cats treated with enrofloxacin (Papich and Riviere, 2009). 
Photosensitivity and Achilles tendon rupture has been associated with the use of 
fluoroquinolones in humans but has not been reported in animals (Brown, 
1996). 
1.7.8 Clinical applications 
Quinolones are indicated for the treatment of local and systemic infections 
caused by susceptible microorganisms, particularly against deep-seated infections 
and intracellular pathogens. Therapeutic success has been obtained in 
respiratory, intestinal, urinary, and skin infections, as well as in bacterial 
prostatitis, meningoencephalitis, osteomyelitis, and arthritis. In horses they are 
useful for the treatment of a variety of Gram-negative infections caused by 
susceptible bacteria resistant to alternative, first-choice drugs. Several 
fluoroquinolone products are approved for use in swine to treat respiratory 
disease and Metritis-Mastitis-Agalactia syndrome (Papich and Riviere, 2009). In 
companion animals these drugs can be used to treat a large number of diseases 
such as prostatitis and mastitis caused by susceptible bacteria; urinary tract 
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infections; respiratory infections including rhinitis and pneumonia and 
osteomyelitis and soft tissue infection (Giguère and Dowling, 2013). 
In avian species respiratory and systemic infections caused by avian pathogenic 
Escherichiacoli (APEC) constitute the most prevalent and economically most 
important primary or secondary bacterial diseases (Lutful Kabir, 2010). 
Fluoroquinolones are considered potentially useful drugs in the treatment of 
colibacillosis and other infections caused by E. coli in chickens and turkeys, in 
particular when first and second choice drugs had failed. 
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2. Objectives 
Due to a wide understanding of the effects of antibiotics and the increase 
of the phenomena of microbial resistance to these drugs, a particular attention 
has been devoted, during the last years, to antibacterial use in humans and 
animals and in particular to the methods oriented to a correct evaluation of 
efficacious dosages for a more prudent and targeted use of antimicrobials in 
veterinary species.  
The PK/PD approach gives tools to improve efficacy in field through the 
relationship between the efficacy values of the antimicrobial drug studied in vitro 
( PD) with the main kinetic parameters obtained by studying the fate of a drug in 
a target specie (PK). Therefore the PK/PD relationship can serve to obtain 
estimates of doses that may be needed to achieve a desired clinical response or 
to modify a dosing regimen based upon susceptibility information on the 
considered pathogen. 
The present study was focused on a particular avian species, turkeys that is 
considered a “minor species”, but important in the livestock production of 
Northern Italy. Scarce data exist about the usage of antimicrobial drugs in turkey 
and even less is known about their efficacy. As the limited number of medicinal 
products authorized in this species, antimicrobial therapy is frequently carried 
out with the few products authorized or with drugs “extra-label” used with the 
consequence of increases of selective pressure and also with the possibility of 
cross-resistance within the same pharmacological group of compounds. In this 
regard, the aim of the study is the revision of dosages and schemes of treatment 
of two fluoroquinolones. 
The first step was to optimize and validate a fast, sensitive, and specific liquid 
chromatography-mass spectrometry (LC-MS) method suitable for the detection 
of a wide range of concentrations of different fluoroquinolones from several 
biological matrices as those occurring in pharmacokinetic and residue depletion 
studies (first trial). The developed method was then used for the  quantification 
of fluoroquinolones in plasma and tissue samples of turkeys derived from 
pharmacokinetic studies (second and third trials). 
In the pharmacokinetic trials, three types of oral treatment were considered: 
single oral gavage, that is considered ideal for the pharmacokinetic profiles, but 
is not feasible infield conditions, five days of 10 hours pulsed water medication 
and five days of 24 hours continuous water medication, which are commonly 
used in farms. Pulse administration can be a viable choice for concentration-
dependent antimicrobials, as fluoroquinolones, because it allows to reach higher 
concentration levels in systemic circulation in a shorter time compared to 
continuous water medication. 
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In order to evaluate and eventually recommend a different route of 
administration than the oral one, the subcutaneous administration was also 
carried out. 
To revise the recommended dosage, the EU authorized dose and the doubled 
dose were examined. The double dose was chosen to assess if better results can 
be achieved with the dosage schemes considered. 
The kinetic parameters obtained from the above described trials were correlated 
with MIC of E.Coli field strains, in order to obtain the PK/PD parameters for 
doses optimization. E.Coli is a Gram-negative bacterium responsible of different 
local and systemic diseases of poultry, such as colibacillosis. Mostly, it acquires 
resistance quite easily, in fact it is now resistant to many antibiotics that are used 
as the first line treatment of colibacillosis. The fluoroquinolones are among the 
most effective antimicrobial compounds for poultry pathogens and for 
colibacillosis, in particular, but being the drug of choice for many human 
bacterial diseases, these antimicrobial agents must be considered as last choice 
product  in avian medicine. 
The drugs under consideration were flumequine and enrofloxacin. 
Flumequine is a 1st generation quinolone, that is no longer used in humans 
because similar congeners with broader activity and better tissue distribution are 
available (Crumplin, 1988).However, it is still used in food-producing species to 
control infection caused by various Gram-negative bacteria. It is employed in 
several animal species, including avian species and turkeys, due to its relative low 
cost and good tolerability. 
Figure 1:Chemical structure of flumequine (Jacobs‐Reitsma et al., 1995). 
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Enrofloxacin is a 2nd generation quinolones, approved only in veterinary 
medicine, with an extended spectrum of antibacterial activity and used in food 
and companion animals to control infection caused by various Gram-negative 
bacteria. Ciprofloxacin, its primary active metabolite is also a very potent 
antibacterial used mainly in human medicine. In European Countries, 
enrofloxacin was approved in the 1990s and is still extensively used in poultry 
for colibacillosis treatment, due to its unique effectiveness against multidrug-
resistant avian pathogenic Escherichia coli (Lutful Kabir, 2010). 
Figure 2: Chemical structure of enrofloxacin (Jacobs‐Reitsma et al., 1995). 
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3.1 Abstract 
The study presents a sensitive and reliable confirmatory method for the 
extraction, identification, quantification of five fluoroquinolones (FQ) namely 
enrofloxacin, ciprofloxacin, difloxacin, sarafloxacin and flumequine, in plasma, 
liver, kidney, muscle, skin þ fat, lung and intestinal content from turkeys. 
For the extraction and matrix clean-up of FQ residues from all biological 
matrices, the Quick EasyCheap Effective Rugged Safe (QuEChERS) 
methodology was adopted; only for plasma samples acetonitrile was used. 
The analyses were performed by liquid chromatography with mass spectrometry 
detection (LC-MS). 
LC separation was performed on a C18 Kinetex column (100x2.1 mm, 2.6 µm, 
Phenomenex, CA, USA)with gradient elution using ammonium acetate solution 
(10 mM, pH 2.5) and methanol containing 0.1%formic acid. Mass spectrometric 
identification was done using an LTQ XL ion trap (Thermo Fisher Scientific,CA, 
USA), with a heated electrospray ionization probe, in positive ion mode. 
The method was validated according to the European Legislation (decision 
2002/657/EC) and EMA guideline (EMA/CVMP/VICH/463202/2009); 
selectivity, linearity response, trueness (in terms of recovery),precision (within-
day repeatability and within-laboratory reproducibility), limit of detection, limit 
of quantification, decision limits, detection capability, absolute recovery and 
robustness were evaluated using turkey blank matrices. All data were within the 
required limits established for confirmatory methods except for flumequine 
which presented a recovery value slightly higher than 110% in muscle and 
intestinal content. For all FQs, all the extraction rates were greater than 70% and 
limits of quantification ranged from 1.2 µg kg-1 to 118.8 µg kg-1. 
This fast and robust method was suitable for the identification and quantification 
of FQ residues in tissues, plasma and intestinal content as confirmed by data 
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obtained from incurred samples of turkeys treated at farm for therapeutic 
purposes. 
3.2 Introduction 
In EU, fluoroquinolones (FQs) have been authorized for several 
veterinary species for the treatment of gastrointestinal and respiratory infections 
caused by gram positive and negative bacteria(Barnes, Nolan, & Vaillancourt, 
2008; Riviere & Papich, 2009;Webber & Piddock, 2001). 
In USA, in 2005, ENRO was banned in poultry due to the wide spread of 
resistance in Campylobacter spp., a commensal microorganism or poultry but a 
pathogen for human (FDA, 2005). In EU, the drug is still authorized and largely 
used in poultry (EMA, 2006),despite monitoring plans indicate the increase of 
resistant microorganisms in poultry farms (EFSA, 2010; Piccirillo Dotto, Salata, 
&Giacomelli, 2013; Russo et al., 2012; Walsh & Fanning, 2008).Recently, in the 
North East of Italy, from the surveillance of medication protocols in poultry 
farms, resulted that pulsed water medication was more frequently used than the 
authorized continuous water medication to treat the birds in the sheds. 
Whendifferent dosage, treatment interval or administration route are adopted, 
the residue monitoring on animal carcasses becomes determinant to guarantee 
food safety and high through-put analytical methods are required to process 
large numbers of samples. Moreover, to ensure a prudent use of antimicrobial 
drugs in veterinary medicine, the restriction on drug usage in food producing 
animals cannot be sufficient and the optimal dosage regimen to minimize 
bacterial resistance should always be assessed for an effective treatment 
(AliAbadi & Lees, 2000; Martinez,McDermott, & Walzer, 2006; McKellar, 
Sanchez Bruni, & Jones,2004). In this context, it is very important to have a 
selective, sensitive and rapid method for the determination of FQ concentrations 
in food-producing animals. 
An important and fundamental step for all analytical procedures is the sample 
preparation, especially when complex matrix as animal tissues composed of 
lipids, carbohydrates, proteins, vitamins, phenolic compounds and organic acids 
are used. Several extraction strategies were described in the literature for FQs 
detection in food of animal origin: solid phase extraction (SPE)(Garcés, 
Zerzanová, Kucera, Barrón, & Barbosa, 2006; Hermo,Barrón, & Barbosa, 2006; 
Toussaint, Chedin, Bordin, & Rodriguez,2005; Verdon, Couedor, Roudaut, & 
Sandérs, 2005), liquid to liquid extraction (LLE) (García, Sarabia, Ortiz, & 
Aldama, 2005),solid-phase micro-extraction (SPME) (Huang, Lin, Yu, & Feng, 
2006)and supercritical fluid extraction (SFE) (Shim, Lee, Kim, Lee, & 
Kim,2003), mostly laborious and time consuming techniques with poor 
extraction efficiency and relatively low recoveries (Huan et al.,2012).Recently, 
more innovative FQ extraction technique from different matrices, were applied: 
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pressurized liquid extraction(PLE) from enfant food product (Rodríguez, 
Navarro-Villoslada, Moreno-Bondi, & Marazuela, 2010), microwave assisted 
extraction(MAE) with in situ LLE clean-up from chicken breast muscle (Xuet 
al., 2011), accelerated solvent extraction (ASE) from muscle, liver, kidney of 
swine, bovine, chicken and fish (Huan et al., 2012),dispersive liquid-liquid micro-
extraction (DLLME) from chicken liver (Moema, Nindi, & Dube, 2012) or fish 
muscle (Tsai et al., 2009)and molecularly imprinted polymers (MIP) from 
chicken muscle or eggs (Blasco & Picò, 2012; Qiao & Sun, 2010) and 
QuEChERS technology. The QuEChERS (QUick, Easy, CHeap, Effective, 
Rugged and Safe)extraction and clean-up approach, attracted great interest in the 
last few years because it allowed to reduce and simplify the time needed to 
complete the processes; initially applied to the analysis of pesticides 
(Anastassiades, Lehotay, Stajnbaher, & Schenck, 2003)was subsequently 
extended to veterinary drug residues extraction from different biological matrices 
(Lopes, Reyes, Romero-González,Frenich, & Vidal, 2012; Stubbings & Bigwood, 
2009).QuEChERS technique was adopted for the extraction of FQs from milk 
(Karageorgou, Myridakis, Stephanou, & Samanidou, 2013;Lombardo-Agüí, 
Gámiz-Gracia, Cruces-Blanco, & García-Campaña,2011), eggs (Capriotti, 
Cavaliere, Piovesana, Samperi, & Laganà,2012; Garrido Frenich, Aguilera-Luiz 
Mdel, Martínez Vidal, &Romero-González, 2010), honey (Lombardo-Agüí, 
García-Campaña,Gámiz-Gracia, & Cruces-Blanco, 2012; Wang & Leung, 2012), 
chicken muscle (Lopes et al., 2012), bovine muscle and swine muscle (Nakajima 
et al., 2012).The objective of the study was to optimize and validate a fast, 
simple, sensitive, and specific LC-MS/MS/MS method suitable for the detection 
of a wide range of concentrations of FQs as those occurring in pharmacokinetic 
and residue depletion studies from several matrices. In the present study, five 
FQs (enrofloxacin, ENRO;ciprofloxacin, CIPRO; difloxacin, DIFLO; 
sarafloxacin, SARA; flumequine,FLUME) were extracted from plasma, lung, 
intestinal content, muscle, liver, kidney, skin þ fat from turkeys, applying one 
single LLE to plasma samples and QuEChERS clean-up procedure to the other 
matrices. For the validation purposes, all the five FQs above reported were used 
and the biological matrices were obtained from healthy never treated turkeys; all 
the incurred samples were obtained from turkeys experimentally administered 
with ENRO and FLUME via pulsed medicated water as reported in previous 
studies by Ferraresi et al. (2013) and Cagnardi et al. (2014). 
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3.3 Materials and methods 
3.3.1.Animals and treatments 
The study was conducted according to Italian law(D.L.116/1992)and was 
ethically approved by the Italian Health Ministry (Animal Welfare Unit, 
2009R4KM4F_002).Thirty-two female turkeys (breed B.U.T.6) 63e79 days old, 
weighing about 4e6 kg and determined to be healthy by a thorough physical 
examination, were used. Turkeys were randomly assigned to 4 groups of 8 
animals to be subjected to treatments with the FQs: groups 1 and 3 were 
repeatedly treated for 5 days via drinking water in a 10-h pulsed scheme 
administration with ENRO (Baytril oral solution 10%, BAYER, Milano, Italy) at 
the dose of20 mg kg-1 b.w. while groups 2 and 4 were treated for 5 days via 
drinking water in a 10-h pulsed scheme administration with FLUME(Flumechina 
40% DOXAL) at the dose of 30 mg kg-1 b.w. (Cagnardi et al., 2014; Ferraresi et 
al., 2013). The doses selected were double the recommended doses of ENRO 
(10 mg kg-1 b.w.) and FLUME(15 mg kg-1 b.w.) in poultry. Plasma and tissue 
samples used as blank matrices were collected from healthy, never treated 
animals from an organic farm. For groups 1 (ENRO) and 2 (FLUME), blood 
samples were collected on days 1 and 5, immediately before the treatment, at 1, 
3,6, 9 h during the 10-h treatment, and at 1, 2, 4, 8, 14 h after the withdrawal of 
medicated water. Plasma was separated by centrifugation at 2000 rpm for 10 min 
and stored at -20 °C pending analysis. Three and 5 days after the last treatment, 
turkeys of group1 and 2 respectively, were sacrificed and liver, kidney, 
muscle(breast), skin þ fat, were collected and stored at -80 °C before analysis. 
Animals of groups 3 and 4 were sacrificed 24 h after the last treatment and lung 
and intestinal content were collected and stored at -80 °C before analysis. 
3.3.2.Chemical and reagents 
Enrofloxacin (ENRO, purity: 99.0%), ciprofloxacin (CIPRO, purity:99.9%), 
difloxacin (DIFLO, purity: 99.8%), sarafloxacin (SARA, purity:97.2%) 
flumequine (FLUME, purity: 99.7%) and norfloxacin (internal standard, NOR, 
purity: 99.7%) were obtained from Sigma-Aldrich(Steinheim, 
Germany).Acetonitrile (ACN) and methanol (MeOH) were from Carlo Erba 
Reagents. Formic acid (FA, 98%), ammonium acetate (98%), potassium 
phosphate monobasic KH2PO4 were from Sigma-Aldrich(Steinheim, Germany). 
All reagents were of analytical grade. Ultrapure water generated by the Milli-Q 
system (Millipore) was used. SampliQ Quick Easy Cheap Effective Rugged Safe 
(QuEChERS) EN buffered extraction kits and SampliQ QuEChERS dispersive-
SPE2 ml tube for drug residue in meat (containing 25 mg of C18 and150 mg of 
anhydrous MgSO4) were used for the analysis of FQs in turkey matrices (liver, 
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kidney, muscle, skin þ fat, lung, intestinal content) and were purchased by 
Agilent (Santa Clara, CA, USA).Phenex-RC (Regenerated Cellulose) syringe 
filters 0.22 µm(Phenomenex, Torrance, CA, USA) were used to filter the extracts 
before the injection in the LC-MS system. 
3.3.3.Standards and stock solutions 
Individual stock solutions of ENRO, CIPRO, DIFLO, SARA, FLUME,NOR 
(IS) were prepared at a concentration of 1000 µg ml-1 by dissolving the proper 
quantity of each compound, exactly weighted, in methanol with 10% (v/v) of 
NaOH into volumetric flasks. These solutions were stored at 4 °C in amber glass 
and prepared fresh every 6 months. Working solutions (containing all FQs 
except of the IS) used to spike blank samples of turkey, were prepared by 
appropriate dilutions of the concentrated stock standard solutions with mobile 
phase (10 mM ammonium acetate pH 2.5:0.1% formic acid in methanol, 
80:20).From IS stock solution, different dilutions were prepared to spike 
matrices: IS at 3 µg ml-1 for plasma, IS at 160 µg ml-1 for kidney and liver, IS at 
100 µg ml-1 for muscle, lung, skin þ fat and intestinal content. 
3.3.4.Instrumentation 
All analyses were performed by liquid chromatography with mass spectrometry 
detection (LC-MS).The chromatographic separation was achieved using an 
Accela600 HPLC pump with CTC automatic injector (Thermo Fischer 
Scientific, San Jose, CA, USA) equipped with a C-18 Kinetex (100x2.1 mm, 2.6 
µm) analytical column by Phenomenex (Torrance,CA, USA).The mass detection 
was achieved with an LTQ XL ion trap(Thermo Fischer Scientific, San Jose, CA, 
USA), equipped with a heated electrospray ionization (HESI-II) probe. The 
system was controlled by the X-calibur software (version 2.1), that was also used 
for the data acquisition and analysis. 
Chromatographic and mass spectrometric conditions 
Gradient elution was applied using a 10 mM ammonium acetate adjusted at pH 
2.5 with formic acid as solvent A and methanol with0.1% formic acid (v/v) as 
solvent B. The mobile phase composition(A:B, v/v) was: 80:20 at 0 min, 50:50 at 
10 min, 10:90 at 13 min and kept unchanged until 14 min, 0:100 from 14.50 min 
to 16 min and80:20 from 17 min to 20 min to re-equilibrate the system. The 
sample trays were maintained at 4°C and the flow rate was set on200 µl min-1. 
Standard solutions at 1 µgml-1 of each FQ were infused directly via syringe pump 
with 20 µl min-1 flow rate to the mass spectrometer in order to find 
fragmentation patterns, tuning parameters and MS3 parameters for each analyte. 
Precursor ions, product ions, collision energies and retention times are shown in 
Table 1. 
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Due to the presence of the amino group in most FQs that is easily protonated in 
acidic medium, the ESI source was used in positive mode. The mass analyzer 
was set on the full scan monitoring mode. The following optimum tuning 
parameters were common for all FQs: sheath gas flow 40 arbitrary units, 
auxiliary gas flow 5 arbitrary units; ion spray voltage 3.5 kV; capillary 
temperature 300 °C; capillary voltage 26 V; tube lens 80 V. 
Retention time windows for each analyte were checked daily with a mixture of 
the five FQs in mobile phase. Confirmation was achieved by examination of the 
relative ion intensities of two majorMS3product ions. 
Table 1: Instrument acquisition data for the analysis of FQs by LC-MS/MS/MS; a product ion used for 
quantification; Rt: retention time. 
Analyte Precursor ion 
(m/z) 
Fragmentation 
pattern 
Collision 
energy (%) 
Rt 
(min) 
Enrofloxacin 360 
 
360 > 316 
316 > 288, 245a 
46 
23 5.6 
Ciprofloxacin 332 
 
332 > 288 
288 >268a, 245 
22 
30 5.3 
Difloxacin 400 
 
400 > 356 
356 > 336, 299a 
30 
20 6.2 
Sarafloxacin 386 
 
386 > 342 
342 >322a, 299 
30 
30 6.6 
Flumequine 262 
 
262 > 244 
244 >202a, 176 
40 
25 12.5 
Norfloxacin (IS) 320 
 
320 > 276 
276 >256a, 233 
36 
30 4.9 
3.3.5. Sample preparation 
The plasma samples purification was performed as reported by Ferraresi et al. 
(2013) whereas QuEChERS technology, which consists of two steps, a salting-
out extraction and a dispersive SPE clean-up, was adopted and used for the 
extraction of FQs from all turkey tissues (Núñez, Gallart-Ayala, Martins, & 
Lucci, 2012; Stubbings& Bigwood, 2009). 
Before proceeding with the extraction, IS solution (10 µl) was added to plasma 
samples to obtain IS at 150 µg l-1 final concentration. 
Turkey matrices (liver, muscle, kidney, skin + fat, lung, intestinal content) were 
first chopped into small pieces and homogenized;2 g of samples (1 g for 
intestinal content) were placed into 50 ml centrifuge tubes and added with 50 ml 
of the different IS solutions reported above (see Section 3.3.3.), to obtain IS final 
concentration at4 µg g-1 in liver and kidney and at 2.5 µg g-1in muscle, lung, skin 
+ fat, and intestinal content, respectively. 
An 8 ml volume of 30 mM of KH2PO4 buffer pH 7.0 were added and the tubes 
were agitated for 1 min. To each tube, a 10ml volume of 5% formic acid in ACN 
was added and the tubes were shaken for other 1 min. Then, an Agilent SampliQ 
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QuEChERS EN extraction salt packet was added to each tube and the sample 
tubes were capped tightly and shaken vigorously for 3 min. After centrifugation 
at4000 rpm for 5 min, a 1 ml aliquot of the upper ACN layer was transferred 
into an Agilent SampliQ QuEChERS dispersive-SPE 2 ml tube and the samples 
were vortexed for 1 min and centrifuged at13,000 rpm for 5 min with a micro-
centrifuge. 
The supernatant (700 µl) was transferred to a 15 ml tube and evaporated to 
dryness under a stream of air at 50C with a TurboVap evaporator (Zymarck, 
Hopkinton, MA, USA). The residue obtained was dissolved in 700 µl of mobile 
phase (10 mM ammoniumacetate pH 2.5:0.1% formic acid in methanol, 80:20), 
vortex, mixed, sonicated for 10 min and filtered through a Phenex-
RC(Regenerated Cellulose) syringe filter 0.22 µm (Phenomenex, Torrance,CA, 
USA) before LC-MS/MS/MS analysis. 
Fluoroquinolone concentrations of all incurred and spiked sample were 
quantified with a daily calibration curve prepared in matrix. 
3.3.6. Method validation 
Prior to application to incurred samples, the method was validated according to 
the European Commission Decision 2002/657/EC for the residue depletion 
study in liver, kidney, skin + fat and muscle, and to the EMA guidelines 
(EMA/CVMP/VICH/463202/2009) for the pharmacokinetic and distribution 
study in plasma, lung and intestinal content. Blank biological matrices from 
different untreated turkeys were used. 
Aliquots of blank samples (200 µl for plasma, 2 g for liver, kidney, lung, muscle, 
skin + fat and 1 g for intestinal content) were transferred into a polypropylene 
tubes and spiked with 50 µl of IS and with proper amounts of working solutions 
of FQs to obtain fortified samples at different concentrations (for intestinal 
content, working solutions containing only ENRO, CIPRO and FLUME were 
used). The mixtures were shaken and then the samples were allowed to stand in 
the dark for 30 min at room temperature to permit the interaction between FQs 
and tissues before proceeding with the extraction described in Section 3.3.5 
The following analytical performance parameters were assessed: specificity, 
linearity response, trueness, precision(within-day repeatability and within-
laboratory reproducibility),limit of detection and quantification, decision limits, 
detection capability, matrix effect, absolute recovery and robustness. 
Confirmation of the identities of the FQs was carried out by comparison of the 
chromatographic peak area of two prominent product ions in MS3, with the 
calibration standard at comparable concentrations. Identification was considered 
reliable if the ratio was within the criteria laid down in the European 
Commission Decision. 
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Specificity 
To verify specificity, a representative number of blank biological matrix samples 
of different origin (n = 10-20) were analyzed to check the absence of potential 
matrix interference peaks at the retention time of the target FQs. 
Linearity 
Method linearity was evaluated by preparing six different calibration curves on 
six different days by spiking each of the seven biological matrices from untreated 
turkeys (blank samples) with different FQ mixed standard solutions, before 
proceeding with the extraction. Final concentrations of FQs were different in 
plasma, lung and intestinal content: 2.5, 5, 10, 25, 50, 100, 200 µg l-1, 6.2,12.5, 25, 
50, 125, 250, 500, 1000 µg kg-1 and 12.5, 25, 50, 100, 250,500, 1000, 2000 µg kg-1, 
respectively. 
For each FQ, a different range of concentrations in liver, kidney, muscle and 
skin þ fat, was adopted and final concentrations were reported in Table S1 (see 
Supplementary data).Calibration lines were constructed by plotting the ratio of 
the standard area to internal standard area versus the added concentrations and 
carrying out linear regression analysis. The linearity was considered acceptable 
when the coefficient of correlation was above 0.990 and the evaluation of 
residual was lower than 20%. 
Limit of detection (LOD) and limit of quantification (LOQ) 
For plasma, lung and intestinal content, limit of detection (LOD)and limit of 
quantification (LOQ) were determined as follows: LOD = 3.3 × SD/S; LOQ = 
10 ×  SD/S, where SD is the standard deviation of y-intercepts and S is the 
average slope obtained from the different calibration curves prepared for each 
matrix (Ribani, Collins, & Bottoli, 2007). For kidney, muscle, liver and skin + fat 
LOD values were determined as described above, whereas LOQ for each FQ 
was defined as the smallest measured content of the identified analyte that can 
be quantified with an acceptable precision and trueness 
(EMA/CVMP/VICH/463202/2009) in agreement with the limits reported by 
European Commission Decision. 
Decision limit (CCα) and detection capability (CCβ) 
The Commission of the European Communities, to ensure food safety, has 
established MRLs legally permitted and accepted in liver, kidney, muscle, skin + 
fat for ENRO, CIPRO, DIFLO, FLUME (Council Regulation 2377/90/EEC). 
For these FQs, the decision limit (CCα)and detection capability (CCβ) were 
calculated. As no MRL has been set for SARA in muscle and kidney, CCα and 
CCβ for this FQ were calculated only for liver and skin + fat. 
50 
 
These values were determined by analyzing blank samples fortified around the 
permitted limit in equidistant steps (the calibration curve procedure). CCα was 
calculated as the mean measured concentration at the MRL of each compound 
plus 1.64 times the standard deviation of the within-laboratory reproducibility at 
this concentration; CCβwas calculated as CCα plus 1.64 times the standard 
deviation of the within-laboratory reproducibility at CCα (Verdon, Hurtaud-
Pessel, & Sanders, 2006). 
Table 2: Linearity evaluation and sensitivity data for the FQs detected in this study in the different 
biological matrices (plasma, liver, kidney, muscle, skin + fat, lung and intestinal content): linear 
determination coefficient (R2), limit of detection (LOD) and limit of quantification (LOQ). 
Plasma Liver 
analyte R
2 LOD (g l-1) LOQ  (g l-1) analyte R
2 LOD (g kg-1) LOQ (g kg-1) 
ENRO 0.9999 0.8 2.5 ENRO 0.9999 2.6 12.5 
CIPRO 0.9998 0.5 1.4 CIPRO 0.9998 5.7 12.5 
DIFLO 0.9995 1.5 4.6 DIFLO 0.9993 43.8 118.8 
SARA 0.9998 0.6 1.8 SARA 0.9997 3.3 6.3 
FLUME 0.9996 0.9 2.5 FLUME 0.9997 29.3 50.0 
Kidney Muscle 
analyte R
2 LOD (g kg-1) LOQ (g kg-1) analyte R
2 LOD (g kg-1) LOQ (g kg-1) 
ENRO 0.9999 9.8 18.8 ENRO 0.9995 5.2 12.5 
CIPRO 0.9999 4.1 18.8 CIPRO 0.9995 2.0 12.5 
DIFLO 0.9999 9.7 37.5 DIFLO 0.9990 13.0 37.5 
SARA 0.9998 1.7 6.3 SARA 0.9992 0.5 1.3 
FLUME 0.9996 25.1 62.5 FLUME 0.9988 8.3 50.0 
Skin + fat Lung 
analyte R
2 LOD (g kg-1) LOQ (g kg-1) analyte R
2 LOD (g kg-1) LOQ (g kg-1) 
ENRO 0.9942 4.8 12.5 ENRO 0.9998 2.7 8.2 
CIPRO 0.9998 8.8 12.5 CIPRO 0.9996 2.9 8.9 
DIFLO 0.9969 16.7 50.0 DIFLO 0.9997 2.2 6.8 
SARA 0.9972 0.9 1.2 SARA 0.9998 0.9 2.7 
FLUME 0.9978 22.7 31.2 FLUME 0.9997 1.8 5.4 
Intestinal content 
analyte R
2 LOD (g kg-1) LOQ (g kg-1) 
ENRO 0.9997 3.1 9.5 
CIPRO 0.9997 1.1 3.4 
FLUME 0.9994 4.5 13.8 
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Table 3: Validation results obtained from plasma and lung (CN: Nominal Concentration; 
CV=Coefficient of Variation; REC: absolute recovery; ME: matrix effect). 
PLASMA 
analyte 
CN 
g l-1 
TRUENESS 
(%) 
Within-day 
Repeatability  
(CV %) 
Within-Laboratory 
Reproducibility 
(CV %) 
REC% ± SD ME 
ENRO 2.5 96.0 3.4 10.6 101.6 ± 5.9 1.5 ± 4.0 x 10
-2 
  10 99.0 3.9 5.5 108.5 ± 6.1 0.9 ± 2.0 x 10
-2 
  50 103.8 5.5 7.1 97.3 ± 2.6 0.9 ± 5.0 x 10
-2 
CIPRO 2.5 92.0 8.8 12.6 99.5 ± 7.9 1.0 ± 1.0 x 10
-2 
  10 98.0 6.6 7.2 103.7 ± 14.3 1.0 ± 3.0 x 10
-2 
  50 100.6 6.7 5.7 110.1 ± 11.2 0.9 ± 3.0 x 10
-2 
DIFLO 2.5 96.0 2.2 10.3 105.6 ± 10.9 1.2 ± 5.0 x 10
-2 
  10 101.0 10.5 9.8 101.7 ± 11.0 0.9 ± 3.0 x 10
-2 
  50 103.4 2.9 10.1 102.9 ± 10.9 0.9 ± 2.0 x 10
-2 
SARA 2.5 100.0 8.7 8.0 101.0 ± 9.2 1.0 ± 1.0 x 10
-2 
  10 99.0 7.1 7.2 102.0 ± 5.6 0.9 ± 6.0 x 10
-2 
  50 96.6 3.6 5.3 99.0 ± 10.0 0.9 ± 5.0 x 10
-2 
FLUME 2.5 104.0 4.7 12.2 112.8 ± 1.9 1.2 ± 5.0 x 10
-2 
  10 104.0 2.7 5.9 105.6 ± 14.4 0.9 ± 2.0 x 10
-2 
  50 96.8 3.0 6.2 112.2 ± 10.9 0.9 ± 3.0 x 10
-2 
LUNG 
analyte 
CN 
g kg-1 
TRUENESS 
(%) 
Within-day 
Repeatability  
(CV %) 
Within-Laboratory 
Reproducibility 
(CV %) 
REC% ± SD ME 
ENRO 12.5 96.8 7.9 12.9 95.2 ± 10.5 1.3 ± 9.0 x 10
-2 
  50 100.4 4.4 7.1 87.9 ± 5.2 1.0 ± 1.2 x 10
-1 
  500 96.2 7.9 5.6 87.4 ± 6.6 1.3 ± 5.0 x 10
-2 
CIPRO 12.5 94.4 2.7 10.2 70.6 ± 5.4 1.3 ± 2.1 x 10
-1 
  50 97.6 5.6 5.5 69.1 ± 3.7 1.1 ± 1.5 x 10
-1 
  500 98.2 2.6 3.4 77.9 ± 11.8 1.4 ± 7.0 x 10
-2 
DIFLO 12.5 103.2 4.7 13.1 102.4 ± 9.5 1.3 ± 5.0 x 10
-2 
  50 104.2 5.1 5.5 88.8 ± 6.6 1.0 ± 1.0 x 10
-1 
  500 95.8 3.6 5.2 95.7 ± 10.5 1.1 ± 6.0 x 10
-2 
SARA 12.5 93.6 5.9 6.6 92.3 ± 5.8 1.2 ± 3.0 x 10
-2 
  50 99.4 3.9 7.3 86.6 ± 6.2 1.1 ± 1.3 x 10
-1 
  500 99.5 4.5 4.9 91.4 ± 9.4 1.1 ± 5.0 x 10
-2 
FLUME 12.5 104.8 6.3 9.7 89.4 ± 9.0 1.1 ± 6.0 x 10
-2 
  50 101.6 8.5 11.2 78.9 ± 6.2 1.0 ± 1.3 x 10
-2 
  500 96.5 5.1 6.0 89.8 ± 8.9 1.0 ± 3.0 x 10
-2 
Precision and trueness 
Precision and trueness of the method were determined by performing tests on 
three sets of blank samples fortified with FQs at three different concentrations 
(six replicates each): for plasma, lung and intestinal content, the levels considered 
were 2.5, 10,50 µg l-1, 12.5, 50, 500 µg kg-1and 25, 100, 1000 µg kg-1 respectively. 
The matrices liver, kidney, muscle and skin + fat, for which an MRL has been 
set (see Table S2, Supplementary data), were fortified with FQ concentrations at 
0.5, 1, 1.5 times each respective MRLs. Blank samples of muscle and kidney were 
fortified with SARA at 5, 10, 15 µg kg-1and 50, 100, 150 µg kg-1respectively. 
For each matrix, samples were analyzed on three different days in the same 
laboratory, with the same instrument but by three different operators, 
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corresponding to a total number of 54 samples. The precision of the method has 
been calculated either in terms of within-day repeatability, the variability of 
independent test results obtained on the same day, with the same method on 
identical test items in the same laboratory by the same operator using the same 
equipment, or in terms of within-laboratory reproducibility, the variability of 
independent test results obtained by different operators in different times as 
unique difference from above (Karageorgouet al., 2013; Muscarella, Lo Magro, 
Palermo, & Centonze, 2007). For the matrix intestinal content, due to the limited 
availability of blank material, only within-day repeatability was evaluated. 
Precision was expressed in terms of imprecision and calculated as the variation 
coefficient (CV %) of measured concentrations at each level: CV % = (standard 
deviation/mean measured concentration) × 100. The CV % values for 
repeatability are acceptable if they are below two third of the value calculated 
from the Horwitz equation, whereas for reproducibility, they are acceptable if 
they are below the values calculated from the Horwitz equation (23% if 
concentration is between 100 and 1000 µg kg-1and 16% if the concentrations are 
higher than 1000 µg kg-1). The Horwitz equation is not applicable to 
concentrations below120 µg kg-1, and the values of repeatability and within-
laboratory reproducibility are considered acceptable if they are below 14.7%and 
22% respectively, as suggested by Thompson (2000). 
The trueness, as no certified reference materials for FQs in the turkey tissues are 
available, was evaluated by the recovery of the known amount of FQs added to 
the blank matrices. It was calculated by dividing the mean measured value by the 
fortification level and multiply by 100 to express the result as a percentage. 
According to 2002/657/EC, the trueness should be between 70 and 100% for 
fortification levels between 1.0 and 10.0 µg kg-1, and between 80and 110% for 
fortification levels ≥ 10.0 µg kg-1. 
Absolute recovery and matrix effect 
The absolute recovery of all analytes from all biological matrices was determined 
by comparing the analytical results of extracted FQs from fortified samples (FQs 
and IS were added before the extraction procedure) with unextracted standards 
added at the same concentrations in blank extracts representing100% recovery. 
Matrix effects were evaluated by calculating the peak area of the analytes in the 
presence of matrix (analytes added to blank matrix after extraction), to the peak 
area in absence of matrix (pure solution of the analyte at the same 
concentration). 
Absolute recovery and matrix effect for each analyte were evaluated at three 
different levels (the same concentrations considered for the evaluation of 
precision and trueness), depending on the target biological matrix and FQ (n= 
6). Three sets of samples were used for determination, one consisting of neat 
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standards (set1), one prepared in a blank matrix extract and spiked after 
extraction (set 2) and one spiked before extraction (set 3). Absolute recovery 
(REC %) and matrix effect (ME) were calculated using the formulas: 
REC (%) = set3area/set2area×100; 
ME = (set2area/ISarea) / (set1area / ISarea). 
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Table 4: Validation results obtained from liver, kidney and muscle (CN: Nominal Concentration; CV = 
Coefficient of Variation; REC: absolute recovery; ME: matrix effect). 
LIVER 
analyte 
CN 
g kg-1 
TRUENESS 
(%) 
Within-day 
Repeatability 
(CV %) 
Within-Laboratory 
Reproducibility 
(CV %) 
REC% ± SD ME 
ENRO 100 94.3 3.6 4.6 82.9 ± 4.8 0.9 ± 3.0 x 10
-2 
  200 97.3 7.9 6.5 87.1 ± 4.6 0.9 ± 3.0 x 10
-2 
  300 100.3 3.2 3.8 100.0 ± 4.8 1.1 ± 1.6 x 10
-1 
CIPRO 100 94.2 6.9 6.9 70.0 ± 6.5 1.0 ± 2.0 x 10
-2 
  200 98.9 5.7 7.8 75.1 ± 2.0 1.1 ± 5.0 x 10
-2 
  300 98.4 5.2 6.0 84.2 ± 3.7 1.2 ± 1.5 x 10
-1 
DIFLO 950 97.7 2.2 2.9 86.8 ± 3.8 0.8 ± 8.0 x 10
-2 
  1900 106.9 2.7 4.7 84.8 ± 3.3 1.0 ± 5.0 x 10
-2 
  2850 98.6 3.0 3.9 93.1 ± 4.3 1.2 ± 1.3 x 10
-1 
SARA 50 96.2 10.3 8.1 84.4 ± 7.5 0.7 ± 1.0 x 10
-2 
  100 104.1 6.2 6.5 88.5 ± 1.7 0.9 ± 4.0 x 10
-2 
  150 100.9 4.6 3.4 105.7 ± 2.8 1.1 ± 8.0 x 10
-2 
FLUME 400 91.9 4.7 7.3 95.0 ± 2.2 0.7 ± 4.0 x 10
-2 
  800 98.9 2.6 5.5 97.1 ± 3.3 0.8 ± 2.0 x 10
-2 
  1200 102.1 2.4 2.6 102.5 ± 4.4 0.9 ± 5.0 x 10
-2 
KIDNEY 
analyte 
CN 
g kg-1 
TRUENESS 
(%) 
Within-day 
Repeatability  
(CV %) 
Within-Laboratory 
Reproducibility 
(CV %) 
REC% ± SD ME 
ENRO 150 98.7 1.8 2.9 94.7 ± 3.4 1.0 ± 3.0 x 10
-2 
  300 96.2 1.2 2.4 100.8 ± 11.8 0.9 ± 3.0 x 10
-2 
  450 98.3 1.2 1.3 106.1 ± 9.8 0.9 ± 2.0 x 10
-2 
CIPRO 150 99.6 1.6 4.5 81.3 ± 7.3 0.8 ± 4.0 x 10
-2 
  300 100.3 1.7 5.0 85.9 ± 8.7 0.8 ± 2.0 x 10
-2 
  450 100.4 1.1 2.3 88.8 ± 8.1 0.7 ± 4.0 x 10
-2 
DIFLO 300 99.6 2.1 2.7 99.9 ± 5.7 0.9 ± 5.0 x 10
-2 
  600 99.7 1.9 1.9 102.5 ± 6.7 0.9 ± 4.0 x 10
-2 
  900 101.3 1.8 1.8 108.8 ± 7.2 0.8 ± 3.0 x 10
-2 
SARA 50 99.8 5.2 6.3 108.1 ± 6.5 1.0 ± 8.0 x 10
-2 
  100 101.4 2.0 3.1 103.2 ± 9.1 1.0 ± 8.0 x 10
-2 
  150 100.1 1.8 2.4 101.2 ± 5.9 0.9 ± 6.0 x 10
-2 
FLUME 500 97.9 2.0 3.4 102.6 ± 2.6 0.9 ± 4.0 x 10
-2 
  1000 97.8 2.2 2.8 102.5 ± 7.8 1.1 ± 8.0 x 10
-2 
  1500 98.0 1.1 3.2 106.2 ±7.3 0.9 ± 7.0 x 10
-2 
MUSCLE 
analyte 
CN 
g kg-1 
TRUENESS 
(%) 
Within-day 
Repeatability  
(CV %) 
Within-Laboratory 
Reproducibility  
(CV %) 
REC% ± SD ME 
ENRO 50 90.0 10.0 6.9 92.9 ± 2.7 0.9 ± 2.0 x 10
-2 
  100 103.4 3.7 7.0 99.6 ± 2.3 1.1 ± 5.0 x 10
-2 
  150 104.3 4.7 4.8 98.8  ± 3.0 1.1 ± 5.0 x 10
-2 
CIPRO 50 92.4 4.7 5.2 83.0 ± 5.0 0.9 ± 1.0 x 10
-2 
  100 100.7 4.0 5.6 80.4 ± 3.2 1.2 ± 4.0 x 10
-2 
  150 100.9 4.3 5.6 81.3 ± 3.9 1.2 ± 4.0 x 10
-2 
DIFLO 150 86.1 5.8 7.0 97.9 ± 1.2 0.9 ± 2.0 x 10
-2 
  300 102.8 5.1 7.7 105.0 ± 1.7 1.1 ± 3.0 x 10
-2 
  450 105.0 3.7 9.3 102.3 ± 4.2 1.1 ± 6.0 x 10
-2 
SARA 5 92.0 12.8 10.3 98.1 ± 11.3 0.9 ± 6.0 x 10
-2 
  10 99.0 9.8 9.9 99.9 ± 7.1 1.1 ± 9.0 x 10
-2 
  15 100.7 7.3 9.9 104.5 ± 6.8 1.0 ± 5.0 x 10
-2 
FLUME 200 95.7 6.9 7.5 104.9 ± 2.3 0.9 ± 6.0 x 10
-2 
  400 111.7 6.9 6.5 109.0 ± 1.9 1.2 ± 6.0 x 10
-2 
  600 113.1 4.5 4.8 105.8 ± 2.7 1.1 ± 2.0 x 10
-2 
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Robustness 
The robustness of the method was assessed according to the Youden and Steiner 
approach (Youden & Steiner, 1975). For this purpose, seven reasonable variables 
were chosen in the sample preparation procedure (volume and pH of dilution 
buffer; shaking, centrifugation and sonication time; formic acid percentage in 
acetonitrile and evaporation temperature of the final extract) and slightly 
modified with respect to the standard procedure. For each factor two different 
conditions were adopted. Eight experiments were carried out for the evaluation 
of the seven selected factors by using eight spiked turkey liver samples at the 
MRL. The effect of each factor was calculated by subtracting the mean result 
obtained with the variable at high level and the mean result achieved with the 
factor at low level. The standard deviation of the differences has been calculated 
and compared with the values obtained under within-laboratory reproducibility 
conditions. 
3.4 Results and discussion 
3.4.1. Method validation 
The specificity was assessed by comparing the chromatograms of blank samples 
with those of the corresponding spiked samples to test for endogenous 
interference; no significant endogenous interferent peaks were evident at the 
retention time of the five FQs. The linearity of the calibrations curves in matrix 
was checked at 6different days after calculating slopes and intercepts of each 
individual curve. Good linearity was observed within the concentrations range 
for all FQs in all matrices since the calculated determination coefficients R2 was 
always >0.99 (Table 2) and residual in the range10-20%. The slopes of the 
different calibration curves did not vary considerably and the intercepts were 
near to theoretical zero value, demonstrating good constancy of the measuring 
system. 
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Figure 1: ENRO (+ CIPRO) and FLUME plasma concentration–time profiles at the 5th day of 10-h 
oral pulsed administration. Mean values (± SD) of 8 turkeys. 
 
The LOQs for all FQs in plasma, lung and intestinal content were set according 
to method sensitivity and by far lower than the FQs concentrations in matrices 
from treated turkeys, confirming the method suitability for distribution study. 
The LOQ set in liver, muscle, kidney, skin + fat for all FQs, is significantly lower 
than the respective half MRL: the values werefrom5 to 16 times below these 
limits (Table S2, Supplementary data).Considering the aim of this work and the 
MRL in these matrices, the LOQs were considered acceptable although, based 
on the performance of the analytical method used and on the basis of signal-to 
noise ratio, it was possible to define even lower LOQ values. 
In Table S2 of Supplementary data, the CCα values with an error of 5% 
(probability of false non-compliance ≤ 5%) and the CCβ values with an error of 
5% (probability of falsely compliant samples _ 5%)are reported. The decision 
limit (CCα) and detection capability(CCβ) take into account the variability of the 
method and the statistical risk of making a wrong decision, and allow the 
assessment of the critical concentrations above which the method reliably 
distinguishes and quantifies a substance (European Decision no.657/2002/EC). 
These parameters were established for ENRO, CIPRO,DIFLO, FLUME, in 
liver, kidney, muscle and skin + fat; for SARA, CCα and CCβ values were 
calculated only for liver and skin + fat, because there is no fixed MRL in kidney 
and muscle. For each matrix, the precision of the method was evaluated at three 
different levels of fortification by calculating the CV % of the FQ concentrations 
under within-day repeatability conditions(calculated from six replicated samples 
analyzed on one day), and under within-laboratory reproducibility conditions 
(calculated from batches of 18 samples analyzed on three different days by 
different operators). The results, listed in Tables 3-5, reveal that all CV % values, 
for within-day repeatability and within-laboratory reproducibility, were 
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acceptable, ranging from 1.1 to 14.2% and from 1.3 to 13.1% respectively, for all 
concentrations. 
The trueness of the developed method, expressed as relative recovery, ranged 
from 86.1 to 106.9% for all FQs (Tables 3-5) in agreement with the limits 
reported by Commission Decision 2002/657/EC. The only exception was 
FLUME in muscle with a recovery of111.7% and 113.1% at 1 and 1.5 MRL 
respectively, and of 111.3% at25 µg kg-1 in intestinal content; thus, an 
overestimation of this FQ in muscle and intestinal content could be expected. 
The QuEChERS-based extraction procedure adopted for FQs recovery, from 
different matrices, did not require further clean-up step. For all analytes, the 
absolute recovery ranged from 69.1% to112.8%, with CV % lower than 14.4%, 
all of this confirms the good reproducibility of the method. 
The matrix effects ranged from 0.70 to 1.50, indicating that the analytes are only 
slightly influenced by the matrix of the tissues and by plasma extract as a 
consequence of optimized samples clean-up procedures, optimized 
chromatography conditions and dilution of extracts that allowed to minimize the 
matrix effect due to the different biological matrices considered in this study. 
Results of robustness test indicated that the method was not affected by slight 
variations of some critical factors in the sample preparation procedure and can 
be considered acceptably robust. 
Figure 2: ENRO, CIPRO and FLUME concentrations in plasma, lung and intestinal content after oral 
pulsed administration for 5 days. Mean values (± SD) of 8 turkeys sacrificed at 24 h after the last 
treatment. 
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Figure 3: ENRO concentrations in muscle, kidney, liver and skin + fat from 8 turkeys (T1-T8) after 
oral pulsed administration for 5 days. Animals were sacrificed after three days from the end of 
treatment. CIPRO concentrations higher than LOD (5.7 µg kg-1) were detected only in liver.  
 
Table 5: Validation results obtained from skin + fat and intestinal content (CN: Nominal 
Concentration; CV=Coefficient of Variation; REC: absolute recovery; ME: matrix effect). 
SKIN + FAT 
analyte 
CN 
g l-1 
TRUENESS 
(%) 
Within-day 
Repeatability  
(CV %) 
Within-
Laboratory 
Reproducibility 
(CV %) 
REC% ± SD ME 
ENRO 50 102.2 2.5 10.9 109.6 ± 10.1 0.9 ± 5.0 x 10
-2
 
  100 102.8 5.2 8.2 97.1 ± 4.9 0.9 ± 3.0 x 10
-2
 
  150 101.7 5.9 6.3 99.9 ± 3.6 0.9 ± 2.0 x 10
-2
 
CIPRO 50 99.6 3.8 8.4 102.1 ± 2.4 0.8 ± 1.0 x 10
-2
 
  100 100.7 8.1 5.7 84.2 ± 8.8 0.9 ± 4.0 x 10
-2
 
  150 102.8 9.6 8.9 82.1 ± 5.5 0.9 ± 3.0 x 10
-2
 
DIFLO 200 100.4 3.6 5.2 111.7 ± 6.3 0.8 ± 7.0 x 10
-2
 
  400 97.3 2.5 2.9 101.7 ± 7.9 0.9 ± 6.0 x 10
-2
 
  600 95.8 2.6 2.6 95.2 ± 7.7 1.0 ± 6.0 x 10
-2
 
SARA 5 91.0 14.2 11.0 110.6 ± 4.2 0.9 ± 6.0 x 10
-2
 
  10 102.3 9.3 6.8 107.7 ± 4.9 0.8 ± 6.0 x 10
-2
 
  15 102.8 9.5 7.4 98.1 ± 5.6 0.9 ± 7.0 x 10
-2
 
FLUME 200 101.7 2.4 4.4 110.5 ± 4.4 0.9 ± 6.0 x 10
-2
) 
  400 99.1 5.1 4.8 103.1 ± 13.3 0.9 ± 4.0 x 10
-2
 
  600 105.5 1.7 5.0 99.1 ± 3.2 1.0 ± 6.0 x 10
-2
 
INTESTINAL CONTENT 
analyte 
CN 
g l-1 
TRUENESS 
(%) 
Within-day 
Repeatability  
(CV %) 
REC% ± SD ME 
ENRO 25 104.2 2.4 96.7 ± 11.3 1.1 ± 3.0 x 10
-2 
  100 102.6 3.6 85.2 ± 2.2 1.2 ± 6.0 x 10
-2 
  1000 97.5 3.3 87.4 ± 5.2 1.1 ± 2.4 x 10
-1 
CIPRO 25 99.6 7.0 79.3 ± 6.5 1.0 ± 1.0 x 10
-2 
  100 102.6 1.9 100.2 ± 2.2 0.9 ± 1.0 x 10
-1 
  1000 97.4 2.1 99.3 ± 4.9 0.8 ± 1.3 x 10
-1 
FLUME 25 111.3 6.8 80.6 ± 2,4 1.0 ± 1.0 x 10
-1 
  100 106.5 2.8 92.7 ± 1.7 0.9 ± 1.6 x 10
-1 
  1000 97.7 3.0 94.5 ± 5.4 0.9 ± 1.6 x 10
-1 
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3.4.2. Analysis of samples from treated turkeys 
The validated method allowed to detect ENRO, CIPRO and FLUME 
concentrations in plasma and in the biological matrices obtained from turkeys 
orally treated via 10-h pulsed medicated water for 5 consecutive days with 
ENRO and FLUME. 
ENRO and CIPRO were determined separately but, for pharmacokinetic 
analysis, tissue distribution and depletion study, the sum of ENRO þ CIPRO 
was always considered. The plasma concentration-time profiles of ENRO and 
FLUME at day 5 of pulsed administration are reported in Fig. 1. The FQ 
distribution in target tissues reported in Fig. 2 confirmed the ability of FQs to 
diffuse freely in lungs reaching concentration higher than in plasma together 
with the importance of biliary elimination route for ENRO and FLUME as 
indicated by the great concentrations of the two FQs in intestinal content at the 
last day of treatment. 
ENRO concentrations in muscle, kidney and skin + fat at 3 days after treatment, 
were always lower than the corresponding MRL and, in several turkeys, lower 
than the LOQ values (Fig. 3). 
With the exception of skin + fat, no large variability of ENRO concentrations 
was observed in the different tissues from treated birds. As reported by San 
Martín, Cornejo, Iragüen, Hidalgo, and Anadón (2007), quinolones accumulate 
in follicles and feathers can become a long lasting reservoir; thus, the variability 
observed in skin + fat can be related to the accidental occurrence of a few small 
feathers. 
No figures are reported for flumequine as after 5 days of withdrawal time, its 
concentrations were always lower than LOQ(average concentration:10.8 µg kg-1) 
despite the double dosage administered with medicated water. 
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3.5. Conclusions 
An LC-MS/MS/MS method was developed and validated for rapid and 
simultaneous determination of the five FQs ENRO, CIPRO,DIFLO, SARA and 
FLUME in incurred plasma, liver, kidney, muscle, skin + fat, lung and intestinal 
content from treated turkeys. 
For the first time, the QuEChERS technology was successfully applied for the 
extraction of FQs from matrices such as the lung, skin + fat, kidney and 
intestinal content. 
The method proved to be simple, fast, efficient, stable, precise, accurate and 
robust, providing good validation parameters, such as linearity, limits of 
quantification, precision, trueness and recovery in all the matrices considered. 
The applicability of the method and its good performances were confirmed in all 
the different approach of the study, plasma kinetics, target tissue distribution and 
residue depletion in liver, kidney, muscle, skin + fat, thus making an effective 
and reliable determination of the target FQs in real samples. 
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3.9 Supplementary data 
Table S1: Concentrations of FQs considered for the evaluation of linearity in the different tissues and 
MRL values established for each analyte (there is no MRL for SARA in kidney and muscle).  
LIVER 
analyte Concentrations (g kg-1) MRL (g kg-1) 
ENRO 12.5, 25, 50, 125, 250, 500, 1000, 2000 200 
CIPRO 12.5, 25, 50, 125, 250, 500, 1000, 2000 200 
DIFLO 118.8, 237.5, 475, 1187.5, 2375, 4750, 9500, 19000 1900 
SARA 6.2, 12.5, 25, 62.5, 125, 250, 500, 1000 100 
FLUME 50, 100, 200, 500, 1000, 2000, 4000, 8000 800 
KIDNEY 
analyte Concentrations (g kg-1) MRL (g kg-1) 
ENRO 18.8, 37.5, 75, 187.5, 375, 750, 1500, 3000 300 
CIPRO 18.8, 37.5, 75, 187.5, 375, 750, 1500, 3000 300 
DIFLO 37.5, 75, 150, 375, 750, 1500, 3000, 6000 600 
SARA 6.2, 12.5, 25, 62.5, 125, 250, 500, 1000 -- 
FLUME 62.5, 125, 250, 625, 1250, 2500, 5000, 10000 1000 
MUSCLE 
analyte Concentrations (g kg-1) MRL (g kg-1) 
ENRO 12.5, 25, 50, 125, 250, 500, 1000 100 
CIPRO 12.5, 25, 50, 125, 250, 500, 1000 100 
DIFLO 37.5, 75, 150, 375, 750, 1500, 3000 300 
SARA 1.2, 2.5, 5, 10, 25, 50, 100 -- 
FLUME 50, 100, 200, 500, 1000, 2000, 4000 400 
SKIN + FAT 
analyte Concentrations (g kg-1) MRL (g kg-1) 
ENRO 12.5, 25, 50, 125, 250, 500, 1000 100 
CIPRO 12.5, 25, 50, 125, 250, 500, 1000 100 
DIFLO 50, 100, 200, 500, 1000, 2000, 4000 400 
SARA 1.2, 2.5, 5, 12.5, 25, 50, 100 10 
FLUME 31.2, 62.5, 125, 312.5, 625, 1250, 2500 250 
Table S2: MRL of FQs established in liver, kidney, muscle and skin + fat and CCα and CCβ calculated 
expressed in µg kg-1 (there is no MRL for SARA in kidney and muscle). 
LIVER KIDNEY 
analyte MRL (g kg-1) CC CC  analyte MRL (g kg-1) CC CC 
ENRO 200 226.4 252.7  ENRO 300 313.2 326.3 
CIPRO 200 232.5 265.5  CIPRO 300 320.0 339.6 
DIFLO 1900 2067.4 2234.7  DIFLO 600 624.2 648.4 
SARA 100 109.4 118.8  SARA -- -- -- 
FLUME 800 908.2 1016.4  FLUME 1000 1040.2 1080.4 
MUSCLE SKIN + FAT 
analyte MRL (g kg-1) CC CC  analyte MRL (g kg-1) CC CC 
ENRO 100 114.8 129.5  ENRO 100 124.2 125.1 
CIPRO 100 108.0 115.7  CIPRO 100 109.0 118.0 
DIFLO 300 343.9 387.8  DIFLO 400 439.1 478.1 
SARA -- -- --  SARA 10 12.2 14.2 
FLUME 400 465.9 531.8  FLUME 250 305.8 361.6 
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AUTHORS: C. Ferraresia, L. Lucatello b, V. Meucci c, L. Intorre c, G. Grilli d,A. 
Piccirillo b, E. Russo b, R. Villa a, C. Montesissa  band P. Cagnardi a 
a Department of Health, Animal Sciences and Food Safety, Università degli Studi di Milano, 
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4.1 Abstract 
Flumequine (FLU) is used in the treatment of systemic bacterial infections 
in poultry, including colibacillosis, which is a common disease in turkeys. The 
pharmacokinetic (PK) behavior of FLU administered to 32 healthy turkeys as an 
oral bolus via gavage or as 10-h pulsed administration in drinking water were 
compared, using the authorized dose of 15 mg/kg and the double dose of 30 
mg/kg. The minimum inhibitory concentrations (MIC) of 235 Escherichia coli field 
strains isolated from poultry were determined for pharmacodynamics (PD) to 
develop a PK/PD model. Blood samples were collected at established times 
over24 h, and the obtained plasma was analyzed using a liquid chromatography 
tandem mass spectrometry method that was validated in-house. A 
monocompartmental model and a noncompartmental model were applied to the 
data to obtain the PK results. For both types of administration and both 
dosages, the ratios of the maximum concentration (Cmax)/MIC50 and the area 
under the plasma concentration-time curve (AUC)/MIC50achieved were 
considerably lower than the fluoroquinolone breakpoints usually adopted for 
efficacy. The Cmax/MIC50and AUC0–24/MIC50ratios were, respectively,0.67 ± 0.09 
and 4.76 ± 0.48 and 1.18 ± 0.35and 7.05 ± 2.40 for the 15 and 30 mg/kg bolus 
doses, respectively. After 10-h pulsed administration of 15mg/kg, values of 
Cmax/MIC50, 0.19 ± 0.02 on d 1 and0.30 ± 0.08 on d 5 of therapy were obtained, 
the AUC/MIC50ratios were 2.09 ± 0.29 and 3.22 ± 0.93 on d 1and 5, 
respectively. Higher values were obtained with the doubled dose of 30 mg/kg: 
the Cmax/MIC50ratioswere 0.49 ± 0.11 on d 1 and 0.69 ± 0.18 on d 5; the AUC/ 
MIC50ratios were 5.15 ± 1.15 and 6.57 ± 1.92 on d 1 and 5, respectively. Based 
on these results, FLU administration should be adopted when specific diagnostic 
findings indicate its efficacy, and revising the dosage scheme to comply with the 
prudent and responsible use of antimicrobials in veterinary medicine is advisable. 
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4.2 Introduction 
The turkey (Meleagris gallopavo), although generally considered a minor 
species, is an extremely important livestock in northern Italy. Scarce data exist 
about the usage of antimicrobial drugs in this species, and even less is known 
about their efficacy in this species (Sanders, 2001; Bywater, 2005). 
Because of the limited number of authorized medicinal products for turkeys, 
antimicrobial therapy is frequently performed using a few authorized products. A 
frequent drawback of this approach is the onset of resistant bacterial strains that 
often exhibit cross-resistance for pharmacological groups of compounds. 
Fluoroquinolones (FQ) are widely used to treat pulmonary and enteric diseases 
in poultry (Papich and Riviere, 2009); among these, colibacillosis is considered 
the main cause of economic loss for turkey breeding (Webber and Piddock, 
2001; Barnes et al., 2008). Flumequine (FLU), a second-generation 
fluoroquinolone drug, is useful in the treatment of systemic Escherichia coli 
infections and possibly other infections that are caused by gram-negative bacteria 
in poultry. Despite the availability of newer FQ, FLU is still employed because 
of its relatively low cost and good tolerability, especially in minor species such as 
turkey, for which the cost of therapy is relevant. In avian species, drinking water 
is the most common route of administering mass medication; the treatments can 
be conducted following 2 schemes: continuous administration during the entire 
light period or pulsed administration for a limited period between 4 and 10–12 h 
(Charleston et al., 1998). Individual therapy is reserved for valuable animals and 
breeders for practical reasons, although it represents a prudent use of 
antimicrobials for the limitation of antibiotic resistance in bacteria. Mass therapy 
is reportedly one of the main causes of the development of microbial resistance 
in veterinary species (EMA, 2006; Lohren et al., 2008); an increase in the number 
of FQ-resistant strains of E. coli, Campylobacter, and Salmonella spp. has been 
frequently reported in recent years (Walsh and Fanning, 2008; EFSA, 2010). 
Several scientific and health institutions have expressed serious concern over the 
emergence of FQ resistance, manifesting the need for risk management 
intervention regarding the use of FQ in humans and animals. Due to the 
development of FQ resistance in Campylobacter strains of poultry origin, the Food 
and Drug Administration has banned the use of FQ for the treatment of poultry 
infections since 2005 (FDA, 2005). In the European Union (EU), risk evaluation 
is ongoing, and according to the guidelines for risk management, FQ should be 
reserved for the treatment of clinical conditions that have responded poorly to 
other classes of antimicrobials (EMA, 2006). In addition, better dosage regimens 
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should be determined based on pharmacokinetic/pharmacodynamic (PK/PD) 
integration (Martinez et al., 2006). 
The available data on FLU have mainly concerned species other than turkeys 
and generally involved intravenous, intramuscular, or oral-bolus 
administration(Mevius et al., 1990; Villa et al., 2005). Therefore, pharmacokinetic 
parameters specific for turkeys given medicated water are still lacking, which may 
result infrequent improper dosages. 
To improve the availability of PK data about FLU in turkeys, the present study 
first aimed to evaluate 2different oral treatments (a single oral gavage and 5 d of 
repeated 10-h pulsed water medication) and 2 different doses of FLU (the EU 
authorized dose, 15 mg/kg, and double the EU authorized dose, 30 mg/kg).Oral 
administration by gavage allows precise control of the predetermined dose 
intake, and 10-h pulsed water medication is a frequent dosage scheme in avian 
clinical practice that is easily handled by farmers. 
Finally, to evaluate the effectiveness of FLU against E. coli, the most common 
zoonotic avian pathogen, a PK/PD approach was implemented, correlating the 
PK results after gavage or 10 h-pulsed administration with the MIC determined 
for the 235 E. coli strains isolated from poultry in Italy. 
4.3 Materials and methods 
4.3.1. Birds 
Thirty-two female turkeys (breed B.U.T. 6) that were63 to 79 d old, weighed 
approximately 4 to 6 kg, and were determined to be healthy by a thorough 
physical examination were selected from a farm belonging to an industrial group. 
The birds were housed according to the requirements of the European Union 
(Council of Europe, 2007) and were kept in 4 groups of 8 individuals, housed in 
4 boxes of 5 m2 on wood shavings at 20°C and 65% RH and receiving 16 h of 
light/day. Commercial diets and water were provided ad libitum. Before the 
experiments, the birds did not receive any pharmacological treatment. 
After an acclimatization period of 8 d, the birds were weighed and individually 
marked for identification. The study was conducted according to Italian law(D.L. 
116/1992) and received ethical approval by the Italian Health Ministry (Animal 
Welfare Unit,2009R4KM4F_002). 
4.3.2. Experimental Design 
Flumequine was orally administered to turkeys via gavage as a single bolus or via 
10-h pulsed medicated water for 5 consecutive days at the target dose of 
15mg/kg of BW and at the doubled dose of 30 mg/kg of BW. 
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Food and water were withdrawn 8 h before administration to reduce any 
variability in the absorption due to drug-feed interaction and over dilution of the 
drug. The turkeys were randomly assigned to 4 groups of 8animals each, 
indicated as groups 1, 2, 3, and 4. 
Groups 1 and 2 received FLU (Flumechina 40%DOXAL, Sulbiate MB, Italy) as 
a single oral dosage via gavage at the doses of 15 and 30 mg/kg of BW, 
respectively, whereas groups 3 and 4 were treated via drinking water at the same 
respective doses. The water intake over a period of 10 h was measured for 3 d 
before the treatment. The FLU was added to the water based on the birds’ mean 
weight and mean daily water intake. The medicated water was provided in a 
pulsed scheme for 10 h/d, from 8.00 to 18.00 for 5 d, and was then replaced 
with fresh water. The daily water consumption was measured at the end of the 
pulse period of each day to calculate the mean antibiotic intake. 
For groups 1 and 2 (oral gavage), blood samples were collected from ulnar or 
metatarsal veins in heparinized tubes before treatment and at 0.25, 0.5, 1, 2, 4, 8, 
12, and 24 h post treatment. For groups 3 and 4 (10-hpulsed medicated water 
given for 5 consecutive days),blood samples were collected on d 1 and 5 of 
treatment. Samples were taken immediately before treatment, at1, 3, 6, and 9 h 
during the 10-h treatment, and then at1, 2, 4, 8, and 14 h after the withdrawal of 
medicated water, which was h 11, 12, 14, 18, and 24 after the onset of the 
treatments. Plasma was separated by centrifugation at 1,500 ×g for 10 min at 
20°C and was stored at−20°C, pending analysis. 
4.3.3. Liquid Chromatography–MassSpectrometry Analysis 
The plasma sample purification was performed as reported by Samanidou et al. 
(2005) with slight modifications:200 μl of plasma was spiked with 10 μl of the 
internal standard (IS) Norfloxacin (3 μg/ml) to have a final concentration of 
0.15 μg/ml; afterward, 3 ml of acetonitrile was added. The tubes were briefly 
vortexed and centrifuged at 3,082 ×g for 10 min. The supernatant was 
transferred to another tube and then evaporated to dryness at 50°C. The residue 
was dissolved in200 μl of the mobile phase and filtered through a 0.22-μm pore-
size membrane, and 10 μl was injected into the HPLC system after an 
appropriate dilution. 
An Accela 600 HPLC pump with a CTC automatic injector was used (Thermo 
Fischer Scientific, San Jose,CA). Chromatographic separation was achieved using 
a C-18 Kinetex column (100 × 2.1 mm, 2.6 μm, Phenomenex,Torrance, CA) with 
guard column. The mobile phase consisted of (A) ammonium acetate 
solution(10 mM, pH 2.5) and (B) 0.1% formic acid in methanol. The mobile 
phase composition (A:B, vol/vol) was:80:20 at 0 min, 50:50 at 10 min, 10:90 at 
13 min and unchanged until 14 min, 0:100 from 14.50 to 16 min,80:20 from 17 
to 20 min to re-equilibrate the system. The sample tray was maintained at 4°C. 
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Mass spectrometric analysis (Garces et al., 2006) was performed using a LTQ XL 
ion trap (Thermo FisherScientific, San Jose, CA) equipped with a heated 
electrospray ionization probe (HESI-II) operating in the positive-ion mode 
under the following conditions: sheath and auxiliary gas flow: 40 and 5 arbitrary 
units, respectively; ion spray voltage: 3.5 kV; capillary temperature:300°C; 
capillary voltage: 26 V; and tube lens:80 V. The collision energies that were 
determined to be necessary for fragmentation in MS2 and MS3 of the molecules 
of interest, precursor ions, product ions, and collision energies are shown in 
Table 1. The Xcalibur(version 2.1) data acquisition software from ThermoFisher 
Scientific was used. 
Calibration curves were constructed using pooled turkey plasma obtained from 
untreated animals. The blank plasma was spiked with 10 μL of IS and with FLU 
to obtain a concentration range of 2.5 to 200 ng/ml. Quantification was based 
on the ratios of the peak areas of the analyte to that of IS, and a least-squares 
linear regression analysis was performed to calculate the calibration curves. 
Flumequine (>99% pure) and norfloxacin (>99% pure) were purchased from 
SigmaAldrich (Steinheim, Germany). Other reagents and solvents were 
purchased from Carlo Erba-Reagenti (Milano,Italy). 
Prior to being routinely applied, the method was validated in-house using a set of 
parameters [linearity, within-run and between-run accuracy and precision, limit 
of quantification (LOQ), limit of detection(LOD), and selectivity] that were in 
compliance with the recommendations defined by the European 
Community(Commission Decision 2002/657/EC, 2002) and with the reference 
guidelines defined in other EU and FDA documents (VICH GL 49, 2011). The 
calibration curves were constructed using matrix-matched calibrator samples 
(concentration range: 2.5–200 ng/ml), and the correlation coefficient was always 
r > 0.99 for 6replicates. 
The within-day precision (repeatability) and accuracy were determined by 
analyzing blank samples that were spiked with 2.5 (n = 6), 10 (n = 6), or 50 (n 
=6) ng/ml on the same day. The between-day precision and accuracy were 
determined by analyzing quality control samples [concentration levels: 2.5 (n = 
18),10 (n = 18), and 50 (n = 18) ng/ml] with each batch of analytical samples on 
3 different days. The following mean values were obtained: within-run accuracy 
2.10 ±0.12, 9.8 ± 0.6, and 52.5 ± 2.6 ng/ml and between-run accuracy 2.5, 10.2, 
and 50.5 ng/ml. The results fell within the accepted ranges for precision(within-
run precision: 5.9, 6.03, and 4.9% for 2.5,10, and 50 ng/ml, respectively; 
between-run precision:12.2, 5.9, and 6.2% for 2.5, 10, and 50 ng/ml, 
respectively). 
An LOQ value of 2.5 ng/ml was obtained. None of the values below the LOQ 
were included in the plasma concentration-time curves or in the pharmacokinetic 
analysis. The LOD was defined as the concentration corresponding to a signal-
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to-noise ratio of 3 and was found to be 0.5 ng/ml. The specificity of the method 
was demonstrated because no interference from endogenous compounds was 
observed in the 20 blank samples tested. 
Table 1: Characteristics obtained using mass spectrometry (MS) analysis 
Compound 
Precursor 
ion 
[M-H]
+
 
(m/z) 
Collision 
energy 
MS
2 
(%) 
Precursor 
ion  
MS
2 
(m/z) 
Collisio
n 
energy  
MS
3 
(%) 
Produc
t ion 
MS
3
 
(m/z) 
Flumequine 262 40 244 25 202 
Norfloxacin (internal 
standard) 
320 36 276 30 256, 
233 
4.3.4. Antimicrobial Susceptibility Testing 
The minimum inhibitory concentrations (MIC) of FLU for 235 E. coli strains 
isolated from poultry in Italy were determined using the broth microdilution 
method according to CLSI (2008) guidelines. 
4.3.5. Pharmacokinetics and Statistical Analysis 
The pharmacokinetic parameters were deduced from the plasma concentration-
time data using the Win-NonLin 6.1 software (Pharsight Corporation, 
MountainView, CA), which allows both compartmental and noncompartmental 
analyses of experimental data. Minimum information criterion estimation 
(Yamaoka et al.,1978) was used to choose the best-fitting model for the data. All 
of the data points were weighted by the inverse square of the fitted value. The 
plasma concentrations after a single oral bolus were fitted to a standard 
monocompartmental model, and also noncompartmental analyses were 
conducted. The kinetics after the 10-hpulsed administrations was determined at 
d 1 and 5using a noncompartmental analysis (Gibaldi and Perrier,1982). 
The peak concentrations, Cmax, and the time to peak, Tmax, were obtained from 
the experimentally observed data. The elimination half-life was calculated as 
ln2/λn, and the mean residence time (MRT) was determined using the following 
equation: MRT = AUMC/AUC, where AUMC is the area under the moment 
curve and AUC is the area under plasma concentration-time curve. 
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The pharmacokinetic parameters are reported as the mean values (±SD). The 
harmonic mean values and pseudo-SD were calculated for the half-lives using a 
jack-knife technique (Lam et al., 1985). The normality of the kinetics data was 
assessed using the Kolmogorov–Smirnov test. The differences between the 2 
bolus gavage doses (group 1 vs. 2), the two 10-h pulsed doses (group 3 vs. 4) and 
the 2 administrations methods(groups 1 vs. 3 and 2 vs. 4) were compared using a 
2-tailed unpaired t-test; P < 0.05 was considered statistically significant 
(GraphPad Prism version 4.00software, San Diego, CA). 
The following PK/PD indices were calculated as predictors of the success or 
failure of the therapy: the Cmax/MIC and AUC/MIC ratios (Toutain et al., 
2002;McKellar et al., 2004). The breakpoint values of Cmax/MIC50 = 8–10 and 
AUC/MIC5= 100 h were considered representative of the therapeutic efficacy of 
this antimicrobial class to prevent the development of resistant bacterial strains 
in poultry (Anadon et al., 2001;Dimitrova et al., 2007; Ozawa et al., 2010). 
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4.4Results 
4.4.5.Single Bolus Gavage Administration (Groups 1 and 2) 
The mean plasma concentrations +SD of FLU at the various sampling times 
after oral gavage administration of both doses adopted are shown in Figure1. 
The individual plasma concentration-time profiles were similar, and a low inter 
individual variability was observed, particularly in group 1, whereas a larger inter 
individual variability was observed when the double dose was administered 
(group 2). The maximum concentrations were reached at approximately 2 h in 
both groups; the drug concentrations rapidly decreased, but the drug was still 
detectable at 24 h after administration, with mean concentrations of 0.26 ± 0.11 
μg/ml (group 1) and 0.72 ± 0.74 μg/ml (group 2).The pharmacokinetic 
parameters obtained from the mono- and noncompartmental analyses are 
presented in Table 2. 
Figure 1. Mean values + SD in the plasma concentration–time profiles of flumequine in group 1 (filled 
triangles) and group 2 (filled squares), which were given the dosages of 15 mg/kg b.w. or 30 mg/kg 
b.w., respectively, via gavage. 
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Table 2: Pharmacokinetics parameters in turkeys1 
Parameter  
Group 1 
(oral gavage 
15 mg/kg) 
Group 2 
(oral gavage 
30 mg/kg) 
Group 3 
(oral pulsed  
15 mg/kg; d 1)  
Group 3 
(oral pulsed 
15 mg/kg;d 5) 
Group 4 
(oral pulsed 
30 mg/kg;d 1) 
Group 4 
(oral pulsed 
30 mg/kg;d 5) 
Tmax (h) 1.88±0.35‡,§ 1.75±0.46#,$ 5.75±2.71€ 6.00±1.60€ 6.75±2.12† 6.38±1.92† 
Cmax 
(µg/ml) 
10.76±1.50‡,§,
† 
18.93±5.65#,$ 3.05±0.36€,# 4.81±1.30€,$ 7.89±1.73‡,†,$ 
10.84±2.92†,§,
# 
AUC0-∞ 
(h*µg/ml) 
74.10±7.98† 123.07±48.72€ ― ― ― ― 
AUC0-24 
(h*µg/ml) 
76.14±7.69‡,§,
† 
112.73±38.40€ 33.46±4.65€,§,# 
51.54±14.87‡,€
,$ 
82.33±18.40‡ 105.18±30.71§ 
AUMC0-24 
(h*h*µg/ml) 
418.04±64.65
‡ 
545.94±275.35
# 
257.60±39.23€,
§,# 
418.88±100.6‡
,$ 
676.31±153.6‡
,† 
878.45±309.29
§ 
t ½ elim (h) 4.01±0.57
*
 4.25±1.60
*
 ― ― ― ― 
MRT 0-24 (h) 
5.48±0.48  
‡,§ 
4.62±1.26#,$ 7.69±0.34€ 8.28±0.64€ 8.23±0.62† 8.27±1.00† 
MIC50 (µg/ml) for Escherichia coli  16 (0.015 to >256) 
  
 
Cmax/MIC50 0.67±0.09† 1.18±0.35#,$ 0.19±0.02#
)
 0.30±0.08$ 0.49±0.11‡,†,$ 0.68±0.18†,§,# 
AUC/MIC50 4.76±0.48‡,§,† 7.05±2.40€ 2.09±0.29§,# 3.22±0.93‡,€,$ 5.15±1.15‡ 6.57±1.92§ 
1Tmax = observed time for Cmax; Cmax = maximum concentration; AUC0-∞ = area under the concentration versus time 
curve from 0 to infinity; AUC0–24 = area under the concentration versus time curve from 0 to 24 h; AUMC0–24 = area 
under moment curve; t1/2 elim. = elimination half-life; MRT0–24 = mean residence time; MIC50 = minimum inhibitory 
concentration 50%; *harmonic mean ± pseudo SD. 
‡Significantly different (P < 0.05) from group 3, d 1. 
§Significantly different (P < 0.05) from group 3, d 5. 
†Significantly different (P < 0.05) from group 2. 
#Significantly different (P < 0.05) from group 4, d 1. 
$Significantly different (P < 0.05) from group 4, d 5. 
€Significantly different (P < 0.05) from group 1. 
4.4.6 10-h Medicated Water Administration for 5Consecutive Days (Groups 3 
and 4) 
In groups 3 and 4, the medicated water concentration was adjusted daily based 
on water intake; nevertheless, the daily measurements of water intake showed 
that the mean dose received by the turkeys was lower than the targeted doses of 
15 and 30 mg/kg of BW (Table3). The mean FLU concentration-time profiles 
following repeated oral administrations of medicated water at the 2 dosages are 
shown in Figures 2 and 3, respectively; the data refer to d 1 and 5 of therapy. In 
both trials, the highest concentrations were achieved on d 5of treatment. The 
pharmacokinetic parameters obtained in the noncompartmental analysis are 
summarized in Table 2. 
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Table 3: Mean values ± SD of doses in turkeys after 10-h pulsed water administration 
Item  
 
Actual dose 
Target dose:15 mg/kg of BW    
d1   12.53 
d 2   7.56 
d 3   9.94 
d 4   14.25 
d 5   15.34 
Mean± SD   11.92±3.18 
Target dose:30 mg/kg of BW    
d 1   15.24 
d 2   14.76 
d 3   20.48 
d 4   26.50 
d 5   23.68 
Mean± SD   20.13±5.15 
Figure 2. Mean values + SD in the plasma concentration–time profiles of flumequine in group 3 at 
days 1 (filled triangles) and 5 (filled squares) following 10-h oral pulsed administration of an average 
dosage of 11.92 mg/kg b.w. for 5 days. 
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Figure 3. Mean values + SD in the plasma concentration–time profiles for flumequine in group 4 at 
days 1 (filled triangles) and 5 (filled squares) following 10-h oral pulsed administration of an average 
dosage of 20.13 mg/kg b.w. for 5 days. 
 
4.4.7.  MIC Determination and PK/PD Integration 
The range of FLU MIC for the 235 poultry-derived E. coli isolates was 0.016 to 
>256 μg/ml. Only 29.8%of the strains were susceptible (n = 70) to FLU, 
whereas70.2% were classified as resistant (n = 165). TheMIC50, defined as the 
minimum inhibitory concentration at which 50% of the isolates were inhibited, 
was16 μg/ml. Based on the PK parameters and the MIC50value,the PK/PD 
integrations were calculated for the different forms of administration; the values 
are presented in Table 2. Significant differences in the Cmax 
/MIC50andAUC/MIC50 ratios were observed when the dose was doubled for the 
gavage and 10-h pulsed administrations and between those at d 1 and 5 of 10-h 
pulsed administration(Table 2). 
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4.5.Discussion 
When given by oral gavage, FLU was very rapidly absorbed, presenting a 
Tmax of approximately 2 h, in contrast to those reported for other FQ, such as 
enrofloxacin and danofloxacin, for which higher values have been recorded 
(Tmax: 6.33 ± 2.5 h for enrofloxacinand 6.0 ± 3.29 h for danofloxacin; Haritova 
et al.,2006; Dimitrova et al., 2007). In our birds, the half-life proved to be rather 
short (t1/2 elim: 4.01 ± 0.57 and4.25 ± 1.60 h), and as expected, was not 
dependent on the dose given. After gavage administration of the 2 different 
doses of FLU, the increase in the Cmax and AUC values was related to the 
increase in the dose, whereas the concentration-time profiles were similar (Figure 
1). 
Oral administration by gavage is not easily practicable in intensive turkey farming 
due to the high population density in the sheds, the need for trained farmers to 
individually handle the birds, and the occurrence of bird stress, despite the 
higher Cmax and AUC0–24 values obtained compared with those obtained using 
medicated water, for which a prolonged intake of lower drug concentrations 
occurs (Table 2). 
The pulsed administration trials showed that theAUC0–24 was increased from d 1 
to d 5 in group 3(AUC0–24 : 33.46 ± 4.65 to 51.54 ± 14.87 h*μg/ml);and that the 
Cmaxin group 4 likewise increased (Cmax:7.89 ± 1.7 to 10.84 ± 2.92 μg/ml). This 
slight increase can be explained by the different intakes of medicated water and 
do not support an accumulation of the drug. Lower intake of the drug was 
observed at the first day of the trial, and medicated water concentrations were 
thus adjusted based on the water intake of the previous administrations. Most 
likely due to the poor palatability of the medicinal veterinary product, the 
targeted doses were never reached using a 10-h pulsed administration. It is likely 
that the availability of unmedicated water during the remaining 6 h of the light 
period affected the animals behavior and that the birds drank less medicated 
water while waiting for the unmedicated water. It is known that increasing the 
concentration of a drug can affect the intake of an adequate amount of the drug 
due to its limited solubility in water and alteration of the water’s palatability; 
moreover, the photoperiod is also a very important parameter that can have 
repercussions for the water uptake and thus on the amount of drug intake 
(Vermeulen et al., 2002). 
Administering the 2 different doses as medicated water allowed a significant 
increase in the Cmax, AUC0–24,and AUC0–24, but not in the Tmax and MRT witht he 
higher dosage; thus a correlation with the increased dosage was observed, 
although the targeted dose of 30mg/kg was not reached. 
In agreement with many previous studies on E. coli resistance to FQ (EFSA, 
2010; Ozawa et al., 2010; Russo et al., 2012), a very high percentage of the 
isolated strains proved to be resistant to FLU. According to our MIC results, 
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70.2% of the E. coli strains tested were resistant. This result suggests that FQ 
should be used in turkeys only when a susceptibility test clearly indicates the 
efficacy of the drug, as proscribed by EMA (2006)and WHO (2011) in the last 
sets of guidelines on the prudent use of antimicrobials. 
Although specific breakpoints have not been defined for avian colibacillosis, 
several studies on FQ in poultry(Anadon et al., 2001; Dimitrova et al., 2007; 
Ozawa et al., 2010) adopted a Cmax /MIC ratio of 8 or 10 and an AUC/MIC 
ratio of 100 as the minimal dose required to prevent the selection of resistant 
bacteria. As reported in Table 2, after gavage administration, the mean 
Cmax/MIC50 and AUC0–24/MIC50 ratios were, respectively,0.67 ± 0.09 and 4.76 ± 
0.48 and 1.18 ± 0.35 and 7.05 ±2.40 for the 15 and 30 mg/kg doses, 
respectively. After the administration of 10-h pulsed medicated water with the 
dosage regimen of 15 mg/kg, lower values of Cmax/MIC50, 0.19 ± 0.02 on d 1 
and 0.30 ± 0.08 on d 5 of therapy were obtained; the AUC0–24/MIC50 ratios 
were2.09 ± 0.29 and 3.22 ± 0.93 on d 1 and 5, respectively. The following 
slightly higher values were obtained with the doubled dose: the Cmax/MIC50 
ratios were 0.49 ±0.11 on d 1 and 0.69 ± 0.18 on d 5; the AUC0–24/MIC50 ratios 
were 5.15 ± 1.15 and 6.57 ± 1.92 on d 1 and 5,respectively. The breakpoints 
values were not reached with either type of administration or dosages, and the 
PK/PD correlation yielded very unsatisfactory results. 
These findings are discouraging but not completely surprising, as FLU was 
licensed for use in food animals at the beginning of the 1980s and has been 
widely used for the mass medication of poultry and because the adoption of 10-h 
pulsed medication is conflicting with its rapid clearance from the blood. 
Based on these results, the EU-authorized dosage of15 mg/kg may be 
ineffective to achieve adequate drug plasma concentrations. Furthermore, the 
10-h pulsed doses of medicated water did not allow reaching plasma 
concentrations that were efficacious in controlling E. coli, due to the long periods 
with unmedicated water. Medicated water should always be provided 
continuously, as reported in the leaflets of the commercial products. To improve 
treatment efficacy and comply with the prudent and responsible use of 
antimicrobials in food-producing species, our results suggest that FLU 
administration should be adopted when specific diagnostic results indicate its 
efficacy and that a revision of the dosage scheme is advisable. 
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5. Enrofloxacin against Escherichia coli in 
turkeys: which treatment scheme is effective? 
AUTHORS: P. Cagnardi ,a C. Ferraresi , a L. Lucatello , b V. Meucci , c                 
L. Intorre , c G. Grilli , d A. Piccirillo , b M. Giacomelli , b and C. Montesissa b 
 a Department of Health, Animal Sciences and Food Safety, Università degli Studi di Milano, 
Milano, Italy b Department of Comparative Biomedicine and Food Science, Università degli 
Studi di Padova, Viale dell’Università 16, Legnaro, PD, Italy c Department of Veterinary 
Sciences, Università di Pisa, 56122 San Piero a Grado PI, Italy and d Department of 
Veterinary Science and Public Health, Università degli Studi di Milano, Milano, Italy. 
5.1 Abstract 
The efficacy of enrofloxacin (ENRO) was evaluated against multidrug-
resistant avian pathogenic Escherichia coli correlating the minimum inhibitory 
concentrations (MIC) of 235 E. coli field strains with its pharmacokinetics (PK) 
in 50 healthy turkeys (5 groups) with a PK/pharmacodynamic approach. The 
treatments were as follows: a) single oral gavage and b) single subcutaneous (SC) 
treatment at the recommended dose of 10 mg/kg; c) single oral gavage, d) 5 d of 
10-h pulsed water medication, and e) 5 d of 24-h continuous water medication at 
the doubled dose of 20 mg/kg. Blood samples were collected at established 
times over 24 h. Plasma was analyzed using a liquid chromatography tandem 
mass spectrometry method that was validated in house. A monocompartmental 
and a noncompartmental model were applied to the data to obtain the PK 
results. After gavage administration, the mean maximum concentration         
Cmax/MIC50 and area under the curve AUC0–24/MIC50 ratios were, respectively, 
3.07•± 0.62 and 7.01•± 1.03 and 25.48•± 3.04 and 57.2•± 3.73 for the        
10 and 20 mg/kg doses, respectively. After SC administration of 10 mg/kg, 
Cmax/MIC50 and AUC0–24/ MIC50 ratios were 3.45•± 0.75 and 33.96•± 7.46, 
respectively. After the administration of 10-h pulsed or 24-h continuous 
medicated water at 20 mg/kg, lower values of Cmax/MIC50 (10-h pulsed:          
3.45•± 0.7; 24-h continuous: 3.05•± 0.48) and AUC0–24/MIC50 (10-h pulsed: 
42.42•± 6.17; 24-h continuous: 53.32•± 5.55) were obtained. Based on these 
results, the European Union-recommended dosage of 10 mg/kg seems 
ineffective to achieve adequate drug plasma concentrations and even the           
20 mg/kg by 10 h pulsed or continuous medicated water administration did not 
reach completely efficacious concentrations in plasma against colibacillosis. 
Although the results obtained were not completely encouraging, the medicated 
water should preferably be provided continuously. To conclude about the 
efficacy of ENRO treatment against colibacillosis, target tissue concentration 
should be extensively considered. 
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5.2 Introduction 
Enrofloxacin (ENRO) is an antimicrobial agent of the fluoroquinolone 
group approved only in veterinary medicine, with a broad antimicrobial 
spectrum and high bactericidal activity (Walker et al., 1992). In European 
Countries, ENRO was approved in the 1990s and is still extensively used in 
poultry for colibacillosis treatment, due to its unique effectiveness against 
multidrug-resistant avian pathogenic Escherichia coli (Bass et al., 1999; Lutful 
Kabir, 2010). 
In avian species, the low economic value of individual birds makes single therapy 
cost-prohibitive and drinking water is the most common route of administering 
mass medication because sick birds continue to drink. For practical reasons, 
individual therapy by oral or parenteral route is reserved for high value breeders 
or small flocks.  
In commercial turkeys, colibacillosis requires a prompt and efficacious 
antimicrobial treatment, preferably via the drinking water. The treatments can be 
conducted following 2 schemes: continuous administration during the entire 
light period or pulse administration for a limited period between a minimum of 4 
and a maximum of 12 h (Charleston et al., 1998). In Europe, turkeys are 
considered a minor species and the cost of the therapy influences strongly the 
choice of the drug. 
In recent years, notwithstanding the scarce information on pharmacokinetics 
(PK) of antimicrobial drugs in turkeys, the ENRO use was increased in this 
species as a result of its effectiveness and the availability of generic products. 
However, an indiscriminate use of these drugs may both select for a resistant 
bacterial population and reduces their clinical efficacy. Mass therapy, frequently 
adopted to cure large numbers of animals, is one of the main causes for the 
development of microbial resistance in veterinary food producing species (EMA, 
2007; Lohren et al., 2008). In poultry, an increase in the number of 
fluoroquinolone resistant strains of E. coli, Campylobacter spp., and Salmonella spp. 
has been frequently reported in recent years (Walsh and Fanning, 2008; EFSA, 
2010). Several scientific and health institutions have serious concern over the 
emergence of fluoroquinolone-resistance, manifesting the need for risk 
management intervention regarding the use of fluoroquinolones in humans and 
animals (EFSA, 2010).  
During the last 10 years, particular attention has been devoted to a correct 
evaluation of efficacious dosages for a more prudent and targeted use of 
antimicrobials in animal species. The correlation between minimum inhibitory 
concentrations (MIC) in field isolates and the PK behavior of antimicrobials in 
target species, known as PK/pharmacodynamic (PD) model is the best tool for a 
prudent and targeted use of antimicrobials (Martinez et al., 2006). 
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The aims of the present study were to evaluate 3 different oral treatments (a 
single oral gavage, 5 d of 10-h pulsed water medication, and 5 d of 24-h 
continuous water medication) and single parenteral (subcutaneous; SC) 
treatment using 2 different doses of ENRO (i.e., the EU authorized dose, 10 
mg/kg, and double the EU recommended dose, 20 mg/kg). The effectiveness of 
different treatment schemes against E. coli was evaluated by a PK/PD approach, 
correlating the PK results with the MIC determined for 235 E. coli strains 
isolated from poultry in Italy reported by Vanni et al. (2014). 
5.3 Materials and methods 
5.3.1. Birds 
Fifty female turkeys (commercial breed, British United Turkeys, B.U.T.6, 
Aviagen Turkeys, Cremona, Italy) 62 to 83 d old, weighed between 3.4 and          
6.9 kg and determined to be healthy by a thorough physical examination, were 
selected from a commercial farm. The turkeys were housed according to the 
requirements of the European Union (Council of Europe, 2007) and were 
divided into 5 groups of 10 individuals kept into 5 pens of 5 m2 on wood 
shavings. The birds were housed at 20°C and 65% RH and received 16 h of 
light/day. Standard commercial diet and water were supplied ad libitum in 
feeders and drinkers. After an acclimatization period of 8 d, the turkeys were 
weighed and individually marked for identification. 
The study was conducted by the Animal Production Research and Teaching 
Centre of the University of Milan (Lodi, Italy) according to Italian law (D.L. 
116/1992) and was ethically approved by the Ethical Committee of University of 
Milan (Opinion n. 31/11). 
5.3.2 Experimental Design 
Enrofloxacin was orally administered to turkeys via gavage as a single bolus at 
the dose of 10 mg/kg of BW or at the doubled dose of 20 mg/kg of BW, or via 
10-h pulsed medicated water, or via continuous administration for 5 consecutive 
days at the doubled dose of 20 mg/kg of BW. Parenteral administration was a 
single SC injection at 10 mg/kg of BW. 
Food and water were withdrawn 8 h before administrations to reduce any 
variability in the absorption due to drug-feed interaction and over dilution of the 
drug and treatments were carried out at the beginning of the light period. One 
hour after single treatments (oral and SC), fresh water and feed were supplied, 
whereas for repeated water medications only feed was supplied after 1 h. 
The turkeys were randomly assigned to 5 groups of 10 birds each, indicated as 
groups 1, 2, 3, 4, and 5.  
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Groups 1 and 2 received ENRO (Baytril oral solution 10%, Bayer, Milano, Italy) 
as single oral dosage via gavage at the doses of 10 and 20 mg/kg of BW, 
respectively. Groups 3 and 4 were repeatedly treated via drinking water at the 
dose of 20 mg/kg of BW for 5 d with ENRO (Baytril oral solution 10%, Bayer). 
The water intake over a period of 10 or 16 h was measured for 3 d before the 
treatment. Enrofloxacin was added to the water based on the birds’ mean weight 
and mean daily water intake. In group 3 the medicated water (ENRO mean 
concentration for 5 d: 179.7 •± 48.7 mg/ ml) was provided in a pulsed scheme 
for 10 h/d from 0700 to 1700 h for 5 d and was then replaced with fresh water; 
in group 4 the medication (ENRO mean concentration for 5 d: 147 •± 1.5 
mg/ml) was provided for 24 h and renewed every morning at 0700 h. The daily 
water consumption was measured at the end of the pulsed period (group 3) or 
before the each day renewal (group 4) to calculate the mean antibiotic intake. 
Birds in group 5 were administered SC at the base of neck with ENRO (Baytril 
injectable solution 5%, Bayer) at the dose of 10 mg/kg.  
Blood samples (maximum 1 ml) were collected from ulnar or metatarsal veins in 
heparinized tubes in all groups as indicated in Table 1. Plasma was separated by 
centrifugation at 1,500 × g for 10 min and stored at −20°C pending analysis. 
Table 1: Treatments, doses and sampling times in all Groups of turkeys  
Group Treatment Dose (mg/kg) Sampling times (h) 
 
1 single oral gavage 10 0, 0.25, 0.5, 1, 2, 4, 8, 12, 24 
2 single oral gavage 20 0, 0.25, 0.5, 1, 2, 4, 8, 12, 24 
3 5 d 10-h pulsed medicated 
water 
5 d actual dose: 15.06 ± 3.33 d 1 and 5: 0, 1, 3, 6, 9, 11, 12, 14, 
18, 24 
4 5 d 24-h continuous 
medicated water 
5 d actual dose: 21.9 ± 2.31 d 5: 0, 2, 6, 9, 12, 15, 18, 20, 24 
5 single subcutaneous 
injection 
10 0, 0.25, 0.5, 1, 2, 4, 8, 10, 24 
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5.3.3 Liquid Chromatography–Mass Spectrometry Analysis and Method 
Validation 
The plasma samples purification was performed as 
reported by Lucatello et al. (2013, 2014). Mass spectrometric (MS) analysis was 
performed on a LTQ XL ion trap (Thermo Fischer Scientific, San Jose, CA), 
equipped as indicated by Lucatello et al. (2013, 2014). The collision energies that 
were necessary for fragmentation of the parent compounds (ENRO and 
ciprofloxacin, CIPRO) into precursor ions (MS/MS) and product ions 
(MS/MS/MS) are shown in Table 2. Calibration curves were constructed using 
pooled turkey plasma obtained from untreated birds. Blank plasma was spiked 
with 10 μl of internal standard (IS) norfloxacin (3 μg/ml) and with ENRO and 
CIPRO to obtain a concentration range of 2.5 to 200 ng/ml. Quantification was 
based on the ratios of the peak areas of the analyte to that of IS and a least 
squares linear regression analysis was performed to calculate calibration curves. 
The method was in-house validated using a set of parameters [linearity, within-
run and between-run accuracy and precision, limit of quantification (LOQ), limit 
of detection (LOD), and selectivity] that were in compliance with the 
recommendations defined by the European Community (European 
Commission, 2002) and with the reference guidelines defined in other European 
Union and FDA documents (VICH GL 49, 2012). The calibration curves were 
constructed using matrix matched calibrator samples (concentration range: 2.5– 
200 ng/ml) and the correlation coefficients was always r > 0.99 for 6 replicates. 
Within-day precision (repeatability) and accuracy were determined by analyzing 
blank samples that were spiked with both compounds at 2.5 (n = 6), 10 (n = 6), 
and 50 (n = 6) ng/ml on the same day. The between-day precision and accuracy 
were determined by analyzing quality control samples, concentration level: 2.5 (n 
= 18), 10 (n = 18), and 50 (n = 18) ng/mL, with each batch of analytical samples 
on 3 different days. The validation results are reported in Table 2 and fell within 
the accepted ranges for validation. All values below the LOQ were not included 
in the plasma concentration-time curves and the pharmacokinetic analysis. 
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Table 2: Characteristics obtained using mass spectrometry analysis and validation results1 
COMPOUND 
Precursor ion 
[M-H]+ 
(m/z) 
Collision energy 
MS/MS 
(%) 
Precursor 
ion  
MS/MS 
(m/z) 
Collision 
energy  
MS/MS/M
S 
(%) 
Product ion 
MS/MS/MS 
(m/z) 
Enrofloxacin  360 46 316 23 245  
Ciprofloxacin 332 22 288 30 245, 268 
Norfloxacin 
(IS) 
320 36 276 30 256, 233 
VALIDATION  
Concentration
g/mL 
Within-run precision(n. 6) Between-run precision(n. 18) 
2.5  ENRO: 7.2%; CIPRO: 11.9 % ENRO: 10.6%; CIPRO: 12.6 
10 ng/mL ENRO: 6.1%; CIPRO: 5 % ENRO: 5.5%; CIPRO:7.2 
50 ng/mL ENRO: 5.5%;CIPRO: 4.7%  ENRO: 7.1%; CIPRO:5.7 
 LOQ LOD 
 ENRO: 2.47 ng/mL; CIPRO: 1.4 ng/mL ENRO: 0.82 ng/mL; CIPRO: 0.46 ng/mL 
1MS= mass spectrometry; ENRO= enrofloxacin; CIPRO= ciprofloxacin; IS= internal standard; 
LOQ=limit of quantification; LOD= limit of detection. 
 
5.3.4 PK and Statistical Analysis 
The PK parameters were deduced from plasma concentration-time data using 
the WinNonLin Prof 6.1 software (Pharsight Corporation, Mountain View, CA), 
which allows both compartmental and noncompartmental analyses of 
experimental data. Minimum information criterion estimation (Yamaoka et al., 
1978) was used to choose the best fitting model for the data. All of the data 
points were weighted by the inverse square of the fitted value. Plasma 
concentrations after single oral bolus, SC, and continuous administration were 
fitted to a standard monocompartmental model and also a noncompartmental 
analysis was carried out. The kinetics after the 10-h pulsed administrations was 
determined at d 1 and 5 using a noncompartmental analysis (Gibaldi and Perrier, 
1982). The peak concentrations, Cmax, and time to peak Tmax were obtained from 
the experimentally observed data. The elimination half-life was calculated as 
ln2/λn; mean residence time (MRT) was determined from the following 
equation: MRT = AUMC/AUC, where AUMC is the area under the moment 
curve and AUC is the area under plasma concentration-time curve. 
Pharmacokinetic parameters are reported as the mean values (±SD). The 
harmonic means and pseudostandard deviations were calculated for half-lives 
using a jack-knife technique (Lam et al., 1985). The normality of the kinetics data 
was assessed using the Kolmogorov–Smirnov test. The differences between the 
2 gavage doses (group 1 vs. 2), and between the 10 mg/kg gavage and the 10 
mg/kg SC (group 1 vs. 5) were compared by a 2-tailed unpaired t-test. The water 
92 
 
medication by 10-h pulsed scheme at d 1 and 5 were compared by a 2-tailed 
unpaired t-test; the same test was used to compare the d 5 of 10-h pulsed and 
continuous administration. A P-value < 0.05 was considered statistically 
significant (GraphPad Prism version 4.00, San Diego, CA). 
The following PK/PD indices were calculated as predictors of the success or 
failure of the therapy: Cmax/MIC and AUC/MIC ratios. MIC50, defined as 
minimum inhibitory concentration at which 50% of isolates tested are inhibited, 
is generally used for PK/PD correlation (Toutain et al., 2002; McKellar et al., 
2004). The breakpoint values of Cmax/MIC50 = 8–10 and AUC/MIC50 = 100 h 
were considered representative of the therapeutic efficacy of fluoroquinolones to 
prevent the development of resistant bacterial strains in poultry. 
5.4 Results 
The CIPRO concentrations were low in all samples from all birds 
reaching approximately 3 to 4% of the parent compound. Therefore, the mean 
plasma concentration-time profiles and PK parameters were reported as the sum 
of ENRO and its metabolite. 
5.4.1 Single Gavage Administration (Groups 1 and 2) 
Mean plasma concentrations ±SD of ENRO of both doses are shown in Figure 
1. Following oral gavage at the dose of 10 mg/kg (group 1) or 20 mg/kg (group 
2), ENRO reached the maximum concentrations at approximately 2 h; 
subsequently, drug levels decreased rapidly, but were still detectable at 24 h after 
administration with a mean concentration of 0.09 ± 0.02 μg/ml (group 1) and 
0.16 ± 0.03 μg/ml (group 2). The pharmacokinetic parameters obtained by 
monocompartmental and noncompartmental analysis are presented in Table 3. 
The Cmax for ENRO after gavage (1.53 ± 0.31 μg/ml and 3.51 ± 0.55 μg/ml in 
group 1 and 2, respectively) were attained at 1.88 ± 0.33 (group 1) and 1.88 ± 
0.99 h (Tmax; group 2). The mean AUC0–24 and half-lives were 12.74 ± 1.52 
h∙μg/ml and 5.27 ± 0.67 h in group 1 and 28.60 ± 2.00 h∙μg/ml and 4.99 ± 0.32 
h in group 2. 
  
93 
 
Figure 1. Mean values + SD in the plasma concentration–time profiles of enrofloxacin in all groups of 
treated birds: group 1 (open triangles, solid line), oral gavage at 10 mg/kg; group 2 (filled triangles, 
solid line), oral gavage at 20 mg/kg; group 5 (filled circles, solid line), subcutaneous (SC) administration 
at 10 mg/kg; group 3 at d 1 (open square, dotted line) and 5 (open squares, dashed line) following 10-h 
oral pulsed administration of an average dosage of 15.06 mg/kg of BW for 5 d and in group 4 (cross, 
dotted line) at d 5 after continuous water medication of 20 mg/kg for 5 d. 
 
Table 3: Pharmacokinetics parameters in turkeys after oral gavage at 10 (group 1) or 20 mg/kg (group 
2) or subcutaneous (SC) administration at 10 mg/kg (group 5)1 
Parameter (Unit) 
Group 1 
Oral gavage 
10 mg/kg 
Group 2 
Oral gavage 
20 mg/kg 
Group 5 
SC 
10 mg/kg 
Tmax (h) 1.88±0.33 1.88±0.99 1.87±0.35 
Cmax (µg/ml) 1.53±0.31
‡
 3.51±0.55
† 
 1.73±0.44 
AUC0-∞(h*µg/ml) 13.13±1.40
‡; §
 29.17±1.97
†
 18.10±3.33
†
 
AUC0-24 (h*µg/ml) 12.74±1.52
‡; §
 28.60±2.00
†
 16.82±4.05
†
 
AUMC0-24 (h*h*µg/ml) 83.43±9.69
‡; §
 179.25±19.85
†
 114.88±36.83
†
 
t ½ elim. (h) 5.27±0.67
*
 4.99±0.32
*
 6.22±1.36
*
 
MRT 0-24 (h) 6.57±0.53 6.26±0.48 6.73±1.32 
MIC50 (µg/ml) for Escherichia coli  0.5  
Cmax/MIC50 3.07±0.62
‡
 7.01±1.03
†
 3.45±0.75 
AUC/MIC50 25.48±3.04
‡; §
 57.20±3.73
†
 33.96±7.46
†
 
1Tmax = observed time for Cmax; Cmax= maximum concentration; AUC0-∞= area under the concentration vs. time 
curve from 0 to infinity; AUC0-24 = area under the concentration vs. time curve from 0 to 24 h; AUMC0-24 = area 
under moment curve; t1/2elim. = elimination half-life; MRT 0-24 = mean residence time; MIC50 = minimum 
inhibitory concentration 50%. 
* harmonic mean ± pseudo SD 
‡ significantly different (P<0.05) from Group 2 
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5.4.2 10-h Medicated Water Administration (Group 3) 
During pulse scheme trials the drug water concentration was adjusted daily based 
on water intake, the measurement of water at the end of 10-h treatment 
indicated that the dose received by turkeys was lower than the targeted 20 mg/kg 
of BW, reaching a value of 14.18 and 16.67 mg/kg at d 1 and 5, respectively; the 
mean dose received by the group was 15.06 ± 3.33 mg/kg. The ENRO mean 
concentration–time profiles following 10-h administration of medicated water 
are shown in Figure 1, the data refer to d 1 and 5 of therapy. The mean kinetic 
parameters obtained by noncompartmental analysis are resumed in Table 4; Cmax 
were attained at about 8 h and the highest concentrations were achieved on d 5 
of treatment (1.28 ± 0.14 µg/ml and 1.72 ± 0.37 µg/ml at d 1 and 5, 
respectively). The mean AUC0–24 at d 1 and 5 were 17.28 ± 2.03 and 21.21 ± 
3.30 h∙µg/ml (P < 0.05), respectively. 
5.4.3 24-h Continuous Medicated Water Administration (Group 4) 
During continuous treatment the drug water concentration was adjusted daily 
based on water intake. The measurement of water at the end of 24-h treatment 
indicated that the dose received by turkeys was between 24.73 and 18.39 mg/kg 
at d 1 and 5, respectively; the mean dose received by the group was 21.9 ± 2.31 
mg/kg. The ENRO mean concentration–time profile at d 5 following 24-h 
administration of medicated water for 5 consecutive days is shown in Figure 1, 
together with the data from all the other scheme of administration. The mean 
kinetic parameters obtained by mono- and noncompartmental analysis are 
resumed in Table 4; Cmax was attained at about 12 h with a mean value of 1.53 ± 
0.24. The mean AUC0–24 and elimination half-life were 26.66 ± 2.77 h∙µg/ml and 
9.78 ± 1.40 h, respectively. 
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Table 4: Pharmacokinetics parameters in turkeys after oral water medication following 10-h (group 3) 
or continuous administration (group 4) at 20 mg/kg 
Parameter 
(Unit) 
Group 3 
Oral pulsed  
20 mg/kg (d 1) 
Group 3 
Oral pulsed 
20 mg/kg (d 5) 
Group 4 
Oral continuous  
20 mg/kg (d 5) 
Tmax (h) 7.88±1.55 8.50±2.33
§ 12.02±2.67
‡
 
Cmax (µg/ml) 1.28±0.14
‡
 1.72±0.37† 1.53±0.24 
AUC0-
∞(h*µg/ml) 
- - 37.37±3 
AUC0-24 
(h*µg/ml) 
17.28±2.03
‡
 21.21±.3.3†; § 26.66±2.77
‡ 
 
AUMC0-24 
(h*h*µg/ml) 
160.07±17.87
‡
 201.72±28.92†; § 309.32±31.33
‡ 
 
t ½ elim. (h) - - 9.78±1.40* 
MRT 0-24 (h) 9.27±0.22 9.53±0.44
§ 11.61±0.23
‡
 
MIC50 (µg/ml) for Escherichia coli  0.5  
Cmax/MIC50 3.07±0.62
‡
 3.45±0.70† 3.05±0.48
‡ 
 
AUC/MIC50 25.48±3.04
‡
 42.42±6.71†; § 53.32±5.55
‡
 
1Tmax = observed time for Cmax; Cmax= maximum concentration; AUC0-∞= area under the concentration vs. time curve from 0 
to infinity; AUC0-24 = area under the concentration vs. time curve from 0 to 24 h; AUMC0-24 = area under moment curve; 
t1/2elim. = elimination half-life; MRT 0-24 = mean residence time; MIC50 = minimum inhibitory concentration 50 
* harmonic mean ± pseudo SD. 
‡ significantly different (P<0.05) from Group 3 day 5 
§ significantly different (P<0.05) from Group 4 
† significantly different (P<0.05) from Group 3 day 1 
5.4.4 Single SC Administration (Group 5) 
Mean plasma concentrations + SD of ENRO after single SC administration at 
10 mg/kg are shown in Figure 1. A low inter individual variability was observed 
in all birds. The ENRO reached the maximum concentrations at approximately 2 
h; subsequently, drug levels decreased rapidly, but were still detectable at 24 h 
after administration with a mean concentration of 0.17 ± 0.03 µg/ml. 
The pharmacokinetic parameters obtained by mono and noncompartmental 
analysis are presented in Table 3. The Cmax of 1.73 ± 0.44 µg/ml for ENRO after 
SC administration was attained at 1.87 ± 0.35 h (Tmax). The mean AUC0–24 and 
half-life were 16.82 ± 4.05 h∙µg/ml and 6.22 ± 1.36 h, respectively. 
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5.4.5 PK/PD Integration 
The PK/PD integrations were calculated for the different trials, based on PK 
parameters and MIC50 value; the values are presented in Tables 3 and 4. The 
MIC50, defined by the broth microdilution method for 235 avian E. coli strains 
isolated in Italy and reported by Vanni et al. (2014), resulted in 0.5 μg/ml, and 
this value was used for PK/PD correlation. Statistical differences (P< 0.05) in 
the Cmax/MIC50 and AUC/MIC50 ratio were observed when the dose was 
doubled for the gavage and only in the AUC/MIC50 ratio between oral gavage 
and SC administration. For the 10-h pulsed administrations, the Cmax/MIC50 and 
AUC/MIC50 ratio were significantly different at d 1 and 5, whereas comparisons 
with continuous administration reported differences for AUC/MIC50 between 
10-h pulsed at d 5 and continuous administration (Table 4). 
5.5 Discussion 
Unlike in other animal species, biotransformation of ENRO into its active 
metabolite CIPRO is low in poultry (Carreras et al., 2004; Dimitrova et al., 2007), 
as also confirmed by the very low amounts of CIPRO recovered (approximately 
3–4% of ENRO) in this study. After gavage administration of 2 different doses 
of ENRO, the increase of Cmax and AUC was related to the dose increase and 
the concentration-time profiles were similar (Figure 1). Enrofloxacin was rapidly 
absorbed, Tmax approximately 2 h, in contrast to what was reported for ENRO 
by Dimitrova et al. (2007) and for danofloxacin by Haritova et al. (2006), where 
higher values were recorded (Tmax: 6.33 ± 2.5 h for enrofloxacin and 6.0 ± 3.29 h 
for danofloxacin). Conversely, similar results were obtained for flumequine by 
the same group of authors (Tmax: 2 h; Ferraresi et al., 2013). The half-life proved 
to be rather short (t 1/2 elim: 5.27 ± 0.67 and 4.99 ± 0.32 h, groups 1 and 2, 
respectively), and as expected, was not dependent on the dose given. 
After SC treatment similar results were obtained, Tmax approximately 2 h and t 1/2 
elim 6.22 ± 1.36 h, the maximum concentrations were also comparable, Cmax 
1.73 ± 0.44 μg/ml (group 5) versus 1.53 ± 0.31 μg/ml (group 1). 
The Cmax and AUC0–24 obtained, which were higher compared with those with 
medicated water (Tables 3 and 4), may indicate that individual treatments by oral 
gavage or SC administration are suitable for efficacious therapy. However, they 
are not easily practicable in intensive turkey farming due to the high bird density 
in the sheds, the need for a high number of trained personnel to individually 
handle the birds, and the stress caused to the birds. This administration route 
should be preferably adopted in small groups of birds or for breeders because 
these have an important genetic impact on the progeny, are expected to live 
longer, and have an high economic value in the flock. In group 3, the pulsed 
administration trial showed an AUC0–24 and Cmax increase at d 5 (AUC0–24: from 
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17.28 ± 2.03 to 21.21 ± 3.30 h∙μg/ml; Cmax: from 1.28 ± 0.14 to 1.72 ± 0.37 
μg/ml, respectively). These results can be explained by an increase in ENRO 
concentrations in medicated water due to the low intake of the drug observed at 
the first day of the trial. In fact, medicated water concentrations were adjusted 
based on the water intake of previous administrations. The achievement of the 
targeted dose of 20 mg/kg was never obtained, likely due to the poor palatability 
of the product and due to the availability of unmedicated water in the remaining 
6 h of light period. It is know that drug intake can vary dramatically due to both 
bird factors (hierarchy, flock size, sex, age, weight, species, breed, health status, 
and so on) and environmental factors (temperature, humidity, feed and water 
availability, photoperiod, and so on; Vermeulen et al., 2002). Comparing these 
results with those by Russo et al. (2012), who assessed the PK of ENRO at the 
10 mg/kg via medicated water in healthy and colisepticemic turkeys, a dose 
proportional increase of Cmax and AUC was observed, whereas Tmax was not 
affected by dosage. In group 4, the drug concentration in water was adjusted 
according to water intake and the dose received by the turkeys (21.90 ± 2.31 
mg/kg) was close to the targeted dose of 20 mg/kg. Notwithstanding the likely 
poor palatability of the water, the lack of fresh water forced the birds to drink all 
the available water and take the targeted dose of ENRO. Compared with pulsed 
administration at d 5, the 24-h continuous administration of ENRO for 5 d 
resulted in a longer Tmax 12.2 ± 2.67 h and MRT of 11.61 ± 0.23 h and higher 
AUC0–24, whereas Cmax was similar. 
In agreement with several studies on E. coli strains isolated from food-producing 
animals, a high percentage of strains has proved to be resistant to ENRO 
(EFSA, 2010; Ozawa et al., 2010). As reported in the co-authored paper by 
Vanni et al. (2014), 38.7% of E. coli tested was resistant, a percentage lower than 
that observed with old generation fluoroquinolones (70.2% with flumequine), 
but confirming an increasing trend since the introduction of fluoroquinolones in 
poultry. The increase in the prevalence of antimicrobial-resistant pathogenic 
bacteria in farm animals requires reevaluation of treatment options. As 
prescribed by EMA (2007) and WHO (2011) in the last sets of guidelines on the 
prudent use of antimicrobials, fluoroquinolones should be used in turkeys only 
when a susceptibility test clearly indicates the efficacy of the drug. It was widely 
accepted that fluoroquinolone dosage regimens that lead to high PK/PD indices 
as AUC/MIC >125 and Cmax/MIC >8 resulted in less frequent selection of 
resistant mutants (McKellar et al., 2004). Although specific breakpoints have not 
been defined for avian colibacillosis, several studies on fluoroquinolones in 
poultry (Anadon et al., 2001; Dimitrova et al., 2007; Ozawa et al., 2010; Ferraresi 
et al., 2013) adopted a Cmax/MIC ratio of 8 or 10 and an AUC/MIC ratio of 100 
as the minimal values required to prevent the selection of resistant bacteria. As 
reported in Tables 3 and 4, neither type of administration reached the breakpoint 
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values and the PK/PD correlation yielded unsatisfactory results. After gavage 
administration, the mean Cmax/MIC50 and AUC0–24/MIC50 ratios were, 
respectively, 3.07 ± 0.62 and 7.01 ± 1.03, and 25.48 ± 3.04 and 57.2 ± 3.73 for 
the 10 and 20 mg/kg doses, respectively. After SC administration 
Cmax/MIC50and AUC0–24/MIC50 ratios were 3.45 ± 0.75 and 33.96 ± 7.46, 
respectively. After the administration of 10-h pulsed (group 3) or 24-h 
continuous (group 4) medicated water with the dosage regimen of 20 mg/kg 
lower values of Cmax/MIC50 (group 3: 3.45 ± 0.70; group 4: 3.05 ± 0.48) and 
AUC0–24/MIC50 (group 3: 42.42 ± 6.17; group 4: 53.32± 5.55) were obtained. 
These results were similar to those obtained by Russo et al. (2012). Conversely, 
data published by Dimitrova et al. (2007) supported the efficacy of 10 mg/kg 
administered via drinking water to turkeys, but PK/PD results were obtained 
correlating the kinetic parameters with a value of MIC first reported in 1996 and 
significantly lower than those adopted in the present study (0.06 versus 0.5 
μg/ml). 
Based on the present results, the EU-recommended dosage of 10 mg/kg might 
be ineffective to achieve adequate drug plasma concentrations. Also the 20 
mg/kg by 10-h pulsed doses of medicated water did not reach plasma 
concentrations that were completely efficacious in controlling E. coli, the 
scenario could be even worse when considering the long period with 
unmedicated water. Indeed, Santos et al. (1997) showed the influence of the 
photoperiod on the PK of drugs during drinking water administration in turkeys. 
The eating and drinking patterns can be altered by the light scheme (Classen et 
al., 1994; Watteyn et al., 2013), which could have a huge influence on the uptake 
of drinking water medication. Although the results obtained were not completely 
encouraging, the medicated water should always be provided continuously, as an 
increase of PK/PD indices was achieved for AUC/MIC. 
Escherichia coli is generally located in the intestine and active ENRO 
concentrations undergo a biliary excretion; thus, plasma concentration does not 
reflect the same magnitude order of intestinal environment. A similar scenario 
should be foreseen for pulmonary infections, against which ENRO is frequently 
used. Indeed, plasma concentrations might not be a good predictor of efficacy, 
as ENRO concentrations and AUC are reported to be higher in lungs than in 
plasma (Tang et al., 2007). In addition, interesting results were obtained during 
the validation process of the LC-MS analytical method by detecting ENRO and 
CIPRO in lung tissue and intestinal content from turkey treated with ENRO 
(Lucatello et al., 2014). Both CIPRO and ENRO concentration in lung and 
intestinal content were much higher than in plasma in turkeys killed after ENRO 
treatment. Therefore, target tissue concentrations need to be evaluated to define 
the efficacy of ENRO treatment against colibacillosis. All the treatment scheme 
evaluated in this study, based on plasma concentration, were not completely 
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satisfactory against E. coli, supporting the unsuitability of the ENRO-
recommended dosage scheme. Thus, to improve treatment efficacy and comply 
with the prudent and responsible use of fluoroquinolones in poultry species, a 
revision of the ENRO dosage scheme, which includes an extensive distribution 
study in the target tissues (i.e., intestine and lung), is advisable for a real efficacy 
evaluation against colibacillosis. 
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6. General discussion 
The emergence of antimicrobial resistance in commensal and pathogenic 
bacteria is a growing concern in both human and veterinary medicine and it is 
primarily correlated with the use of antimicrobials in humans and animals. 
In human and veterinary medicine the use of antimicrobial agents is often 
correlated and many antimicrobials used in humans are often authorized for 
companion and farm animals. This correlation is worrying for the repercussions 
on resistance phenomenon. The deep comprehension of antimicrobial effects 
and the rise of antimicrobial resistance in food producing species and in humans, 
encouraged international agencies to review the use of authorized antimicrobial 
drugs in veterinary and human practice. In human and veterinary medicine many 
studies have been carried out to define precise dosages, to improve drug activity 
and reduce selection of resistance in antimicrobial therapy. Although considered 
ideal, the individual administration is not a viable treatment in poultry breeding 
due to the high number of animals bred and the low cost of individual animals 
compared to the high management cost of individual therapy. Therefore oral 
mass medication is still used and preferred. In poultry the preferred method of 
oral mass treatment is drinking water medication, because ill birds usually tend to 
stop feeding but not drinking. Drinking water therapy can vary dramatically in 
response of efficacy as a function of several factors, such as photoperiod 
schema, chemical characteristics of water and preparation of medical solution. 
Consequently, the underdosing of the drug is likely, and such risk must be 
considered and limited as much as possible (i.e. accurate weighting of the 
animals to determine the correct  drug dosage, correct consideration of water 
intake, etc.). 
Another important aspect to consider in order to optimize antimicrobial therapy, 
is the assessment of the bacterial susceptibility (MIC or antibiogram) aimed at 
knowing whether the selected drug will be effective or not. The potential for 
rapid spread of disease in avian species often needs empirical and rapid 
treatment prior to the results of bacterial culture and susceptibility testing. 
The studies reported in this thesis aimed to evaluate the use of fluoroquinolones 
in turkey to maintain the efficacy and reduce the spread of resistance against 
E.Coli, in accordance with a prudent use of this drugs as suggested by the 
European Guidelines (EMA, 2011). 
In the trials, the pulsed water medication has highlighted the failure to achieve 
the target dose intake by animals, likely due to the poor palatability of the 
products and due to the availability of “clean water” in the remaining light 
period. This is certainly an important aspect that can promote the underdosing 
with consequent increase of selective pressure leading to an increase in the 
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antimicrobial resistance. Therefore the medicated water should always be 
provided continuously during the entire light period. 
The data obtained by oral treatments at two different doses (15 mg/kg and 30 
mg/kg) with flumequine showed how the breakpoints values (Cmax/MIC ratio 
and AUC/MIC ratio) were not reached. Despite its use suggests that clinical 
efficacy is still achievable, the PK/PD correlation yielded very unsatisfactory 
results, especially considering the high MIC values that indicate a widespread of 
antimicrobial resistance. These findings are not totally unexpected, since 
flumequine was licensed for use in food animals over 20 years ago and has been 
widely used for the mass medication of poultry. Following these results, the 
continuous administration with flumequine was not  tested. .In tissue samples  
higher concentrations were achieved and this result are more encouraging and 
can justify the repeated use of this antimicrobial in breeding. It would be 
desirable, since the low sensitivity and the possibility of cross-resistance against 
other fluoroquinolones, that flumequine would be used more prudently in farms. 
The oral treatments and the single parenteral treatment using two different doses 
of enrofloxacin (10 mg/kg and 20 mg/kg) were not completely satisfactory 
against E. coli. To improve the efficacy of the treatment and to comply with the 
prudent and responsible use of fluoroquinolones in poultry species, a revision of 
the enrofloxacin dosage scheme is advisable for a real efficacy evaluation against 
colibacillosis.  
Fluoroquinolones concentrate in the some tissues, as lung and intestine, as 
confirmed by the results of this thesis.  These tissues are target tissue of the 
antimicrobial effects of fluoroquinolones. So as for flumequine, also for 
enrofloxacin this account for the efficacy of the treatment, notwithstanding the 
unsatisfactory results of the PK/PD correlation with plasma results. Based on 
these aspects, further studies on the drug concentrations profile in liver, lung and 
intestinal content would be helpful to allow the integration of PK/PD data, in 
order to evaluate the real efficacy of flumequine and enrofloxacin against 
colibacillosis. 
It should be underlined that the determination of bacterial susceptibility is one of 
the two mainstay for the PK/PD correlation for the evaluation of antimicrobial 
efficacy. Thus the re-examination of susceptibility of bacteria with specific values 
of MIC that become breakpoints for determining “susceptibility”, “intermediate” 
or “resistance” of specific bacteria can help to set realistic values for decision 
making of the correct choice of antimicrobial therapy. The CLSI-VAST 
subcommittee has been setting breakpoints for the new and old veterinary drugs, 
this is an important step forward in the evaluation of antimicrobial therapy, as 
realistic breakpoints are necessary in order to avoid ineffective administration of 
antibiotics that only serve to select for other resistant bacteria and contaminate 
the environment (CLSI, 2013). 
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Finally, the reported studies allowed to highlight important aspects about the 
usage and efficacy of antimicrobial drugs in turkey, that were still lacking. A 
further diffusion of this type of studies is even more relevant for the so called 
“minor species”. It is possible to conclude that fluoroquinolones, and 
enrofloxacin in particular, represent an useful tools for the treatment of various 
infections in turkey, but their efficacy should be accurately monitored due to the 
spreading of resistance in zoonotic bacteria. Moreover, any lack of efficacy 
should be reported by pharmacovigilance and, if possible, the causes should be 
deeply investigated. This can represent an important instrument for monitoring 
drug resistance in the target species and to retain the potential efficacy of 
fluoroquinolones for critically dangerous bacteria. 
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7. Summary 
The importance of prudent and rational use of antimicrobial is important, not 
only to safeguard the efficacy of these drugs in humans and veterinary medicine 
but, even more so, to prevent the emergence and spread of undesirable 
resistance phenotypes in zoonotic pathogens as well as in commensal bacteria 
that can be transmitted between animals and humans. 
Even more importance and attention is now given to the prudent use of 
medically important antimicrobial drugs, referring to those drugs for human 
therapeutic use. 
The fluoroquinolones belong to this category. These are very potent 
antimicrobials and active against a wide range of pathogenic organisms and are 
well distributed in the body after administration. This class of antimicrobials has 
a therapeutic effect on most infections in different organs or tissues. Although it 
is rare that fluoroquinolones are the only available agent for treatment of a 
specific infectious disease, fluoroquinolones are important alternative medicinal 
products for a veterinarian to have as option for treatment. Fluoroquinolones 
have a unique mechanism of action not related to conventional antimicrobials, 
and therefore their efficacy should be retained as long as possible.  
The avian production increased enormously in the last 50 years and the 
European Union (EU) is one of the world's top producers in poultry meat and a 
net exporter of poultry products. In this production, turkeys that is considered a 
“minor species”, but it is important in the livestock production of Italy. Scarce 
data exist about the usage of antimicrobial drugs in turkey and even less is 
known about their efficacy. As the limited number of medicinal products 
authorized in this species, antimicrobial therapy is frequently carried out with the 
few products authorized or with drugs “extra-label” used with the consequence 
of increases of selective pressure and also with the possibility of cross-resistance 
within the same pharmacological group of compounds. 
The studies reported in this thesis aimed to revise the use of fluoroquinolones in 
turkey to maintain the efficacy and reduce the spread of resistance against E.Coli, 
the most common zoonotic avian pathogen. 
Pharmacokinetic(PK)/pharmacodynamics (PD) models are the best tool in order 
to select optimal dosage regimen. To confirm dosages used at farms and allow 
the integration of PK/PD data, the plasma concentrations in blood from healthy 
animals collected during treatment with flumequine and enrofloxacin, were 
determined. 
The first step was to optimize and validate a fast, simple, sensitive, and specific 
liquid chromatography-mass spectrometry (LC-MS)/MS/MS method suitable 
for the detection of a wide range of concentrations of fluoroquinolones as those 
occurring in pharmacokinetic and residue depletion studies from several 
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matrices. The first trial presents a sensitive and reliable confirmatory method for 
the extraction, identification, quantification of five fluoroquinolones . For the 
extraction and matrix clean-up of fluoroquinolones residues from all biological 
matrices, the Quick Easy Cheap Effective Rugged Safe (QuEChERS) 
methodology was adopted; only for plasma samples acetonitrile was used. The 
analyses were performed by (LC-MS. LC separation was performed on a C18 
Kinetex column (100x2.1 mm, 2.6 µm, Phenomenex, CA, USA) with gradient 
elution using ammonium acetate solution (10 mM, pH 2.5) and methanol 
containing 0.1% formic acid. Mass spectrometric identification was done using 
an LTQ XL ion trap (Thermo Fisher Scientific, CA, USA), with a heated 
electrospray ionization probe, in positive ion mode. The method was validated 
according to the European Legislation (decision 2002/657/EC) and EMA 
guideline (EMA/CVMP/VICH/463202/2009); selectivity, linearity response, 
trueness (in terms of recovery), precision (within-day repeatability and within-
laboratory reproducibility), limit of detection, limit of quantification, decision 
limits, detection capability, absolute recovery and robustness were evaluated 
using turkey blank matrices. All data were within the required limits established 
for confirmatory methods except for flumequine which presented a recovery 
value slightly higher than 110% in muscle and intestinal content. For all 
fluoroquinolones, all the extraction rates were greater than 70% and limits of 
quantification ranged from 1.2 µg/kg to 118.8 µg/kg. This method was suitable 
for the identification and quantification of fluoroquinolones in plasma samples 
of turkeys treated for the purpose of second and third trials. 
In the second trial, the PK behavior of flumequine administered to 32 healthy 
turkeys as an oral bolus via gavage or as 5 days of 10-hours pulsed administration 
in drinking water were compared, using the EU authorized dose of 15 mg/kg 
and the double dose of 30 mg/kg. The MIC of 235 Escherichia coli field strains 
isolated from poultry were determined for PD to develop a PK/PD model. 
Blood samples were collected at established times over 24 h, and the obtained 
plasma was analyzed using the LC-MS/MS/MS method previously described. A 
monocompartmental model and a noncompartmental model were applied to the 
data to obtain the PK results. The maximum concentration (Cmax)/MIC50 and the 
plasma concentration-time curve from 0 to 24 hours (AUC0–24)/MIC50 ratios 
were, respectively, 0.67 ± 0.09 and 4.76 ± 0.48 and 1.18 ± 0.35 and 7.05 ± 2.40 
for the 15 and 30 mg/kg bolus doses, respectively. After 10-hours pulsed 
administration of 15 mg/kg, values of Cmax/MIC50, 0.19 ± 0.02 on day 1 and 
0.30 ± 0.08 on day 5 of therapy were obtained, the AUC/MIC50 ratios were 2.09 
± 0.29 and 3.22 ± 0.93 on d 1 and 5, respectively. Higher values were obtained 
with the doubled dose of 30 mg/kg: the Cmax/MIC50 ratios were 0.49 ± 0.11 on 
day 1 and 0.69 ± 0.18 on day 5; the AUC/MIC50 ratios were 5.15 ± 1.15 and 
6.57 ± 1.92 on d 1 and 5, respectively. For both types of administration and both 
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dosages, the Cmax/MIC50 and the AUC/MIC50 ratios achieved were significantly 
lower than the fluoroquinolones breakpoints usually considered for efficacy. 
The last trial involving 50 healthy turkeys, was conducted to evaluate the efficacy 
of enrofloxacin. As in the previous study, the effectiveness of different treatment 
schemes against E. coli was evaluated by a PK/PD approach, correlating the PK 
results with the MIC determined for 235 E. coli strains. 
In this study, 3 different oral treatments (a single oral gavage, 5 days of 10-hours 
pulsed water medication, and 5 days of 24-hours continuous water medication) 
and single parenteral (subcutaneous; SC) treatment using 2 different doses of 
enrofloxacin (i.e., the EU authorized dose, 10 mg/kg, and double the EU 
recommended dose, 20 mg/kg) were evaluated. Blood samples were collected at 
established times over 24 h. Plasma was analyzed using a LC-MS/MS/MS that 
was validated in house. A monocompartmental and a noncompartmental model 
were applied to the data to obtain the PK results. After gavage administration, 
the mean maximum concentration Cmax/MIC50 and area under the curve AUC0–
24/MIC50 ratios were, respectively, 3.07 ±  0.62 and 7.01 ±  1.03 and 25.48± 3.04 
and 57.2 ± 3.73 for the 10 and 20 mg/kg doses, respectively. After SC 
administration of 10 mg/kg, Cmax/MIC50 and AUC0–24/MIC50 ratios were 3.45 ± 
0.75 and 33.96 ± 7.46, respectively. After the administration of 10-h pulsed or 
24-h continuous medicated water at 20 mg/kg, lower values of Cmax/MIC50 (10-h 
pulsed: 3.45 ± 0.7; 24-h continuous: 3.05 ±0.48) and AUC0–24/MIC50 (10-h 
pulsed: 42.42 ± 6.17; 24-h continuous: 53.32 ± 5.55) were obtained. Based on 
these results, the European Union-recommended dosage of 10 mg/kg seems 
ineffective to achieve adequate drug plasma concentrations and even the 20 
mg/kg by 10 h pulsed or continuous medicated water administration did not 
reach completely efficacious concentrations in plasma against colibacillosis. 
Although the results obtained were not completely encouraging, the medicated 
water should preferably be provided continuously. To conclude about the 
efficacy of enrofloxacin treatment against colibacillosis, target tissue 
concentration should be extensively considered. 
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